Treatment modalities in experimentally induced acute liver failure by Ernst, P.T.
TREATMENT MODALITIES IN 
EXPERIMENTALLY INDUCED 
ACUTE LIVER FAILURE 
CIP-GEGEVENS KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Ernst, Pieter Thea 
Treatment modalities in experimentally induced acute liver 
failure I Pieter Thea Ernst. - CS.l. : s.n.J. - Ill. 
Proefschri1t Rotterdam. - Met lit. opg. - Met samenvatting 
in het Nederlands. 
ISBN 90-9002014-4 
SISO 605.13 UDC 616.36+616.36-089.8(043.3) 
Treiw.: leverziekten I levertransplantaties. 
TREATMENT MODAliTIES IN 
EXPERIMENTALLY INDUCED 
ACUTE LIVER FAILURE 
BEHANDEUNGSVORMEN BU EXPERIMENTEEL 
GEINDUCEERD ACUUT LEVER FALEN 
PROEFSCHRIFT 
TER VERKRUGING VAN DE GRAAD VAN DOCTOR 
AAN DE ERASMUS UNIVERSITEIT ROTTERDAM 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR A.H.G. RINNOOY KAN 
EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. 
DE OPENBARE VERDEDIGING ZAL PLAATS VINDEN OP 
WOENSDAG 6 JANUARI 1988 TE 14.00 UUR 
DOOR 
PIETER THEO ERNST 
GEBOREN TE 's-GRA VENHAGE 
1988 
DRUKKERIJ PASMANS B.V., 's-GRAVENHAGE 
PROMOTIECOMMISSIE: 
PROMOTOR: PROF. DR D.L. WESTBROEK t 
PROMOTOR: PROF. DR O.T. TERPSTRA 
OVERIGE LED EN: PROF. DR H.A BRUINING 
PROF. DR W.C. HULSMANN 
The publication of this thesis was financially supported by B. Braun Medical 
Nederland b.v. and Zeiss Nederland b.v. 
B. BRAUN MEDICAL B.V. 
Margrietstraat 1, 5401 CH Uden 
Telefoon: 04132 • 51355 
To the memory of Professor D. L. Westb.roek 
To my wife Gea and my son Pieter Benjamin 
.:- j. 
-f._ 
' 

CONTENTS 
CHAPTER 1: GENERAL INTRODUCTION 
1.1. Research on hepatocellular regeneration 
1.2. Experimental treatment modalities in acute 
hepatic failure 
1. 3. Experimental liver insufficiency 
CHAPTER 2: MATERIALS AND METHODS 
2. 1 . Animals 
2.2. Induction of hepatic failure 
2.3. Uridine treatment 
2.4. Isolation of hepatocytes 
2.5. Hepatocyte culture 
2.6. Implantation of hepatocytes into the spleen 
and abdominal cavity 
2.7. Preparation of hepatocyte fractions 
2.8. Auxiliary partial liver transplantation 
2 . 9. Parameters 
2.9.1. Biochemistry 
2.9.2. ·Histology 
2.9.3. Function test 
2.10. Statistical analysis 
13 
14 
15 
18 
18 
18 
19 
21 
21 
22 
22 
25 
25 
26 
26 
CHAPTER 3: DOSE-RESPONSE RELATION OF GALACTOSAMINE 
IN VARIOUS RAT STRAINS 
3. 1. Dose-response relation and survival rate of 
galactosamine in WagjRij and BN rats 27 
3.2. Selection of a sutrlethal dose of galactosamine 
for WagjRij on the basis of liver function tests 30 
3.3. Dose-response relation of galactosamine in 
Wag/Cbp, Cpb:Wu, and Lewis rats 32 
3.4. Conclusions 35 
CHAPTER 4: EFFECTS OF DIFFERENT TREATMENT MODALITIES 
ON THE SURVIVAL RATE OF WAG jRIJ RATS 
4.1. Treatment with hepatocytes injected into 
the abdominal cavity 
4.2. Treatment with hepatocyte fractions 
4.3. Treatment with cell-free supernatant 
4.4. Treatment with hepatocytes implanted 
in the spleen 
4.5. Conclusions 
CHAPTER 5: METABOLITE DEFICIT PERIOD 
5.1. Determination of an effective metabolite 
deficit period 
5.2. Conclusions 
CHAPTER 6: EFFECTS OF THE DIFFERENT TREATMENT MODALITIES 
ON DETERIORATING LIVER FUNCTION 
IN WAG /RIJ RATS 
6.1. Treatment with hepatocytes injected 
into the abdominal cavity 
36 
37 
41 
41 
45 
47 
53 
54 
6.2. Treatment with cytosol 
6.3. The fate of hepatocytes injected into the 
peritoneal cavity or the spleen 
6.4. Treatment by implantation of hepatocytes 
6.5. 
CHAPTER 7: 
in the spleen 
Conclusions 
EFFECTS OF TRANSPLANTATION OF HEPATOCYTES 
AND CYTOSOL ON DETERIORATING LIVER FUNCTION 
IN LEWIS AND CPB: WU RATS 
7.1. Lewis rats treated by implantation of 
hepatocytes in the spleen 
7.2. Lewis rats treated with cytosol 
7.3. Cpb:Wu rats treated with cytosol 
7.4. Conclusions 
CHAPTER 8: AUXILIARY PARTIAL LIVER TRANSPLANTATION 
8.1. Transplantation of normal liver tissue 
into normal rats 
8.2. Transplantation of normal liver tissue 
into rats treated with galactosamine 
8. 3. Conclusions 
CHAPTER 9: GENERAL DISCUSSION 
SUMMARY 
SAMENVATTING 
REFERENCES 
LIST OF ABBREVIATIONS 
ACKNOWLEDGEMENTS 
CURRICULUM VITAE AUCTORIS 
57 
59 
62 
64 
65 
66 
69 
69 
71 
72 
78 
80 
87 
90 
93 
101 
102 
104 

11 
CHAPTER 1 
GENERAL INI'RODUCTION 
==================== 
Despite the availibility of a number of treatment modalities, 
the mortality associated with acute hepatic failure remains high. The 
syndrome of acute hepatic failure is rare ( 67, 92) but the reported 
mortality rate ranges from 60 to almost 100% (4,67). The management 
of this hepatic syndrome is challenging but difficult, as the 
persisting high mortality rate indicates. The basic therapeutic 
approach to acute hepatic failure is still a combination of intensive 
care, monitoring, treatment of complications, artificial replacement 
or addiction of functions, and detoxification to prevent accumulation 
of the liver damage (72). Restoration of the patient's "internal 
milieu" is the main goal of the treatment, which is aimed at reducing 
the development of hepatic encephalopathy, the prevention of the 
cerebral edema which is the major cause of death ( 12) , and the 
promotion of regeneration of the organ. 
Liver regeneration is a process by which the liver restores 
damage it has undergone and which usually leads to normal functioning 
in all respects. Over 60% of the cells in the liver are hepatocytes. 
If part of the liver is excised in experiments done in rats, the 
hepatocytes in the remaining part soon show mitosis and the liver 
regains its normal size in approxima:tely three weeks (26,45). If the 
hepatocytes are damaged by a nutritional deficiency, a toxic 
substance, or a viral infection, all of the mechanisms essential for 
the regeneration of functional hepatic tissue may be able to function 
in a harmonious way and thus restore the complicated normal 
architecture of the organ (31). The mechanism which determines the 
composition of the cell population of the liver is still obscure, and 
the restorative capacity of the organ is limited (12). When the 
number of damaged hepatocytes or the total hepatocellular damage 
exceeds a certain limit which has not yet been established exactly, 
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the mechanism required for regeneration is not triggered. Several 
factors are probably involved in the processes underlying 
regeneration of the liver (39,40,82,88). According to Leffert (40), 
there are seven possible regulators of rat liver regeneration. Koch 
,and Leffert reported (33,40) that increases in the influx of Na+ ions 
mediate rat hepatocyte proliferation. It has also been postulated 
that a ca2+ flux induced by glucagon and insulin or insuline-like 
substances, is associated with elevated cAMP levels and thus triggers 
the liver regeneration. The possible regulators of rat liver 
renegeration involved can be divided in two main categories: the 
common regenerating stimulating factors i.e. , the tissue-specific 
growth factors, and factors of hormonal origin ( 40, 41, 6 9) , and the 
hepatotrophic factors which secretion is possibly regulated by the 
injured liver involved (10,20,22,53,61,81). 
An injured liver that has undergone damage exceeding the 
critical threshold and is therefore unable to regenerate 
spontaneously, can sometimes be stimulated to regenerate by the 
administration of substances derived from donor liver tissue, as has 
been extensively reviewed (2,46,52,53,60,62-68,78,81,83,86,88,90). 
When the critical point has been reached and the process has become 
irreversible and will terminate in necrosis, the only solution is 
replacement of liver function by transplantation. There are also 
situations in which the injury itself is not irreversible but that 
the recovery time will be too long to permit survival. In the latter 
case treatment should be aimed at minimizing the process of 
destruction in the liver; in the first place to create sufficient 
time for the liver to regenerate and in the second place to stimulate 
the organ's remaining capacity to regenerate. However, replacement of 
the liver function by transplantation temporary or from an artificial 
device is still provisional (29,93). 
It has been supposed that liver cells could functionally reach 
the "point of no return" and still have some degree of potency to 
regenerate if the appropriate stimulatory factors were brought into 
play ( 17, 77) . 
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1.1. Research on hepatocellular regeneration 
Many attempts have been made to identify the underlying factors 
playing a key role in the regeneration of liver tissue ( 10, 22, 33, 
37,38,81-83). Homogenates (9) of liver tissue and/or suspensions of 
liver cells injected intra'peritoneally induced to an increase in the 
rate of mitosis in the liver, and the effect of homogenates of liver 
tissue of young animals was considerably greater than that of adult 
rats. Thier and Ravanti (89) reported that the critical factors were 
thermo-unstable and organ-specific. Investigations performed by 
Blomquist (9) showed that suspensions of regenerating liver tissue 
(collected 48 hours after 70% hepatectomy) and suspensions of normal 
liver tissue of young rats increased the mitotic rate in the liver 
after intraperitoneal administration. Marczek (53) investigated the 
effects of polypeptides isolated from intact and regenerating rat 
livers on thymidine incorporation. Intact liver yielded fractions not 
only inhibiting but also stimulating liver DNA synthesis in vitro. The 
DNA synthesis stimulating capacity of fractions derived from 
regenerating liver (collected 24 hr after partial hepatectomy) showed 
a considerable increase which was accompanied by an almost total loss 
of the DNA synthesis inhibiting properties of the fractions in 
question. Both inhibitory and stimulatory fractions were found to 
contain polypeptides with molecular weights in the range of 50-500 kD 
(20,37,61). 
The studies concerning improvement of liver regeneration have 
pointed to the following factors as critical for stimulation of the 
process of liver regeneration: 1. the age of the donor rats when a 
suspension of normal liver tissue is administered; 2. the interval 
between the preparation of the extract of regenerating liver tissue 
and the time when it is administered; and 3. the time of day at which 
the extracts were prepared ( 10) . Labreque and co-workers reported 
(37,38) that the time at which the extracts were prepared during the 
day was an essential parameter for the ability to demonstrate any 
stimulatory activity at all. 
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Thus, the research in this field has .shown that a variety of 
factors play a critical role in the capacity of an experimental model 
to reveal how hepatotrophic factor(s) operate. 
1.2. Experimental treatment modalities in acute hepatic failure 
Several investigators have reported that treatment with isolated 
viable hepatocytes (15,48,50-52,62,79), or hepatocyte fractions 
deriving from normal or regenerating liver tissue (2,46,47,60,63-
66,88) can improve the survival of rats suffering from toxin-induced 
acute hepatic failure. Stimulation of the regeneration of 
deteriorating liver tissue by factors secreted by transplanted liver 
cells seems to be the underlying mechanism here rather than the 
provision of temporary metabolic support. 
These studies differed from those mentioned above, which were 
done in normal heal thy rats rather than rats suffering from acute 
hepatic failure. 
Makowka and co-workers reported that intraperitoneal 
implantation of syngenic, allogenic, and xenogenic hepatocytes reduced 
the mortality rate of rats suffering from toxin-induced liver 
insufficiency (50,52). Reduction of the mortality rate from 80-100% to 
20-30% has been reported (51). Cytosol prepared from normal and 
regenerating liver tissue significantly enhanced the survival rate in 
rats with acute liver failure (20,46,47,60,63,64,88), whereas in other 
animals the same cytosol preparation significantly inhibited the 
hepatic regenerative response normally seen in rats 20-24 hr after 
partial hepatectomy. Baumgartner and 0 1 Neill showed that cell-free 
supernatant of hepatocyte cultures improved the survival rate of rats 
suffering from acute hepatic failure (2,65,66). 
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1.3. Experimental liver insufficiency 
For experimental purposes, liver injury can be induced in a 
variety of animal species by the administration of 2-deoxy-2-amino-
D-galactose (d-galactosamine). This compound has proved to be highly 
suitable for use in studies on acute hepatitis (14). Galactosamine 
hepatitis has been accepted as a good experimental model, superior in 
several respects to models based on many other hepatotoxic agents such 
as tetrachlorcarbon, thioacetamide, and dimethylnitrosamine ( 14, 6 8) 
for the following reasons: a gOod dose-effect relationship is obtained 
and the effect is restricted to the liver. No morphological or 
functional alterations have been observed in other organs after the 
administration of doses of galactosamine sufficient to cause liver 
lesions. The target selectivity of this amino sugar is due to the 
local abundance of metabolizing enzymes (14). 
Figure 1 . 1 shows the metabolic pathway of galactosamine ( 14) . 
GALACTOSAMINE 
.... 
galactosamine·1·phosphate (liver) 
.... 
UDP • GaiN, • GleN,- GaiNac,- GlcNac 
.... 
depletion of hepatic UTP 
.... 
depression of uracil nucleotide dependent biosynthesis 
(RNA; proteins; glycoproteins; glycolipids; glycogen) 
.... 
organelle injury 
.... 
necrosis liver cells 
Fig. 1.1. 
Pathway of galactosamine metabolism 
Uridine-galactosamine 
Uridine-glucosamine 
Uridine diphosphate N-acetyl-galactosamine 
Uridine diphosphate N-acetyl-glucosamine 
Uridine 5'-triphosphate 
(UDP-GalN) 
(UDP-GlcN) 
(UDP-GalNac) 
(UDP-GlcNac) 
(UTP) 
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During the first 30 min after administration of galactosamine to 
rats, the level of UDP-amino sugars rises . A marked change in the 
relative concentrations of the individual uracil nucleotides leads to 
a strong depression of the hepatic levels of UTP, UDP, UMP, UDP-
glucose, UDP-galactose, and UPD-glucuronate. Galactosamine-induced UTP 
deficiency is highly selective. No reduction of pools of ATP, GTP, or 
CTP has been observed. This is in contrast to many other experimental 
conditions, where a deficiency of UTP is associated with a general 
depression of nucleoside triphosphates. 
UTP deficiency depresses uracil nucleotide dependent 
biosynthesis, which terminates in organelle injury and cell necrosis. 
Injury to the hepatocyte plasma membrane is considered to be the best-
defined cause of hepatocellular necrosis and may represent the 
terminal event of many mechanisms (68, 76, 77). Galactosamine induces 
structural and functional changes in rat liver plasma membranes, and 
these alterations have been associated with changes in the calcium 
content of the injured cells (17). 
Several blood plasma parameters can be used for the quantitation 
of hepatocellular injury and necrosis. Typical hepatological 
laboratory findings include elevated levels of liver-specific enzymes 
and increased bilirubin concentrations in the blood plasma. Many of 
the coagulation factors present in serum are synthesized by the liver 
and have a short half-life value. The markedly prolonged prothrombin 
time as well as the associated hemorrhages indicate impaired function 
of the galactosamine-treated liver. The histological findings show a 
rapid loss of liver glycogen (14). 
A single dose of galactosamine (1 mmol/kg = 215 mg/kg) induces 
light-microscopically detectable alterations which 4 hr later are 
characterized by acidophilic degeneration of the cytoplasm (14, 76). 
Necrosis of single hepatocytes is evident 6 hr after the injection of 
galactosamine. After 24-26 hr, all of the signs of spotty necrotic 
hepatitis are found. Foci of hepatocellular necrosis are disseminated 
over the lobules, and the hepatocytes have been replaced by 
inflammatory infiltrates containing mainly segmented leukocytes, 
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lymphocytes, and plasma cells. Acidophilic degeneration and 
acidophilic bodies are frequently observed. The liver of animals 
surviving for 7 to 12 days after galactosamine administration shows 
nonmal histological features (14). 
Evidence yielded by these studies led to the investigations 
reported in this thesis, which concerned the effect of the 
transplantation of hepatocytes or the administration of hepatocyte 
fractions, cytosol, or cell-free supernatant on the process of 
hepatocellular deterioration induced by galactosamine. 
These studies were done in connection with the problems 
encountered in the treatment of acute hepatic failure. The effect of 
transplantation of hepatocytes and hepatocyte fractions on survival 
was studied in rats suffering from acute hepatic failure, as a step 
toward evaluation of the method for clinical use in patients with 
acute hepatic failure. 
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CHAPTER 2 
MATERIAL AND METHODS 
2.1. Animals 
Male rats of the inbred WagjRij, BNjRij, WagjCpb, and Lewis/Cpb 
strains and the outbred Cpb:Wu strain with a body weight between 220 
and 290 g were used. The animals were fed ad libitum with standard 
laboratory pelleted rat diet throughout the experiments and had free 
access to water. They were kept at a constant temperature and given 
an artificial daylight cycle. 
2.2. Induction of hepatic failure 
Liver injury was induced by the administration of 
d-galactosamine [2,4].(SIGMA, St.Louis, Mo, USA)(d-GL). Galactosamine 
was dissolved in distilled water (200 mgjml) (0,93 mol/1) and 
neutralized with 1N NaOH to pH 7. 0. The solution was injected 
intraperitoneally immediately after preparation. 
2. 3 . Uridine treatment 
Galactosamine traps the essential cofactor uridine triphosphate 
(UTP) (32). With the appropiate dosage and schedule of administration, 
a lethal liver-cell necrosis can be induced with galactosamine. 
Administration of uridine together with or shortly after 
galactosamine gives protection against or reverses the UTP deficiency 
as well as tl:J.e disturbed synthesis of RNA and protein 
(14,18,32,68,76,77) (Fig.1.1). 
Uridine (BDH Chemicals, Poole, UK) was dissolved in distilled 
water (200 mgjml) and 125, 500, 1000, or 2000 mgjkg (0.5-8.2 mMol) 
was injected intraperitoneally at various time-points (0, 6, 12, 18 
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anQ. 24 hr) after galactosamine administration. 
2.4. Isolation of hepatocytes 
The two-step perfusion method used was a modification of the 
procedure described by Seglen (74). In short the rats were 
anesthetized with ether, the abdomen was prepared for surgery, and 
heparin ( 0 . 2 rnl ThrornboliquineR, ORGANON, Oss, The Netherlands, 5000 
IU/rnl) was injected via the tail vein. The liver was exposed through 
a midline incision extended by transverse incisions to the left and 
right. The portal vein and infrahepatic caval vein were isolated. 
Loose ligatures were placed around the portal vein proximal to its 
junction with the pancreatico-duodenal vein and around the 
infrahepatic caval vein proximal to its junction with the renal 
veins. The portal vein was cannulated with a teflon catheter 
(BraunuleR VasofixR 16 G, B. BRAUN, Melsungen, W-Gerrnany) . The 
infrahepatic caval vein was transsected and perfusion of the liver 
with a ca2+...,free salt solution (NaCl: 142 mmoli KCl: 6.7 mmoli HEPES: 
10 rnrnbl) at a constant flow of 20 rnljmin and 370c was started. It 
appeared that for optimal perfusion of the liver, the outflow of the 
perfusion fluid must be led through the suprahepatic caval vein. 
The chest was then opened and the suprahepatic caval vein 
cannulated with a teflon catheter, after which the loose ligature 
around the infrahepatic caval vein was tightened and the isolated 
liver was perfused for 10 min. Next, the perfusate was changed to a 
collagenase solution (50 rnl Hanks' balanced salt solution containing: 
collagenase (SIGMA,IA) 25mg, CaCl2.2H20 27 mg, and HEPES (1 Mol) 
2. 5 rnl, which was recirculated for 15 min under continuous gassing 
with oxygen and carbon dioxide. The liver was then removed and cut 
with a razor blade into small pieces which were brought into an 
Erlenmeyer flask provided with a stopper permitting continuous 
gassing. The cell suspension was incubated in a shaker ( 40 
strokes/min) at 370c for 15 min, filtered through two nylon filters 
(100 and 250 nini MonodurR), and washed three times by centrifugation 
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at 20 g for 5 min each, in fresh Hanks' medium at 40c. Viability was 
always determined by The trypan blue exclusion test, i.e., the cells 
were scored according their ability to exclude trypan blue. The yield 
of hepatocytes from one liver varied from 200 to 300x106 cells with a 
viability of 80 to 90 percent. Addition of hyaluronidase and DNAse to 
the perfusion fluid (5) did not improve the yield, confirming reports 
by other investigators. Of critical importance was immediate washout 
of blood after the start of the perfusion. This prompt evacuation of 
blood, which was demonstrated by the even white color of the liver, 
proved to be the most essential factor with respect to the yield and 
viability of the isolated hepatocytes. 
Figure 2. 1 shows a number of isolated hepatocytes. A darkly 
stained dead hepatocyte, a nucleolus, and a few healthy hepatocytes 
can be seen in this micrograph. 
All glassware was siliconized (silicone solution, SERVA, 
Heidelberg, W-Germany). The final volume of the cell suspension was 
adjusted to give 20x106 cells/ml for intraperitoneal injection and 
40x106 cellsjml for intrasplenic injection. After isolation, the 
cells were immediately injected intraperitoneally, via a teflon 
catheter. 
Fig. 2.1. 
Micrograph showing a few hepatocytes after isolation and exposure to 
trypan blue to assess viability. 
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2.5. Hepatocyte culture 
During the course of the experiments the viability of the 
hepatocytes was assessed several times with another test, as follows. 
After some of the cells in a given sample had been injected into the 
rats, part of the remaining portion was cultured for 24 hr according 
to standard techniques. These cell cultures were perfo.nned in 
collaboration with the Department of Cell Biology of Erasmus 
University (Dr.M.P.Mulder). The percentage of cell attachment at 4 hr 
was about 80 and the morphology of the cells 24 hr after plating, as 
observed with a phase-contrast microscope (Fig.6.4), showed whether 
the rats had received viable hepatocytes. 
For the preparation of cell-free supernatant, isolated 
hepatocytes were cultured by plating (2x1o6 cells/plate) on 4 ml 
medium composed of RPMijHEPES (Flow, 1460) containing 10% fetal calf 
serum, 20 uM dexamethasone, 10 uUjml insulin, 0.8 mM CaCl2, 50 ugjml 
penicillin, and 50 ugjml streptomycin. The culture dishes were placed 
in a water-saturated 95% 02, 5% C02 atmosphere and the culture medium 
was changed at 4-hr intervals. The cell-free supernatant of the 
cultures which was stored at -so0c, was used for studies on the 
effect on acute hepatic failure of the hepatotrophic factors secreted 
into the medium by the isolated hepatocytes during culture. 
2.6. Implantation of hepatocytes into the spleen and abdominal cavity 
Isolated hepatocytes (20-30x106) in suspension were implanted in 
the spleen by injection of a cell suspension ( 40x1o6 cells per ml) 
into the pulp via a 25-gauge needle, after occlusion of the celiac 
artery. The clamp was released five minutes after the injection. 
Isolated hepatocytes ( 40x106 cells) were injected into the 
abdominal cavity as a cell suspension (20x1o6 per ml) was injected 
via a teflon catheter (BraunuleR VasofixR 16G). 
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2.7. Preparation of hepatocyte fractions 
Livers of donor rats were excised and suspended immediately into 
medium ( 1: 1, wjv) at 40c (medium: glucose 5%, HEPES 50 mM) ; · The 
liver tissue was homogenized (Ultra-TUrraxR type TD 18-10), and 2 ml 
of this crude homogenate was injected intraperitoneally. 
For the cytosol preparation, crude homogenate was centrifuged at 
1000 g for 10 min and the supernatant was centrifuged at 100,000 g 
for 60 min (both steps at 40c) . A 1-ml aliquot of the final 
supernatant was then injected intraperitoneally. The total protein 
content of 1 ml cytosol ranged between 60 and 80 mg, which is roughly 
the equivalent of 50x1o6 cells. For the preparation of crude 
homogenates or cytosols of regenerating liver tissue, a suspension 
was made of the remaining part of the donor livers 24 or 72 hr after 
a 70% partial hepatectomy had been performed according to Higgins and 
Anderson ( 2 6) . 
2. 8. Auxiliary partial liver transplantation (APLT) 
Donor rats had the same body weight as the acceptor. Preparation 
of the donor for the operation was performed under ether anesthesia. 
The al::domen was opened by a midline incision. After a 70% hepatectomy 
had been performed and the common bile duct was ligated close to the 
liver hilus, the portal vein was dissected from surrounding 
structures as far as the superior mesenteric vein. Next, loops were 
placed around the vessels and around the portal vein proximal to the 
superior mesenteric vein as well as around the hepatic artery. The 
inferior caval vein was dissected and encircled at the segment 
between the right renal vein and the liver. Heparin was given 
intravenously (0.2 ml ThromboliquineR, 5000 IU/ml). 
Five minutes after the heparin injection all of the loose 
ligatures were tightened and the thorax was opened. The suprahepatic 
caval vein was dissected from surrounding structures and a ligature 
was placed as close to the heart as possible. The liver was removed 
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by cutting the diaphragm and the hepatic ligaments, taking care not 
to damage the liver capsule. The donor liver was placed on a glass 
tray which was put on ice. The infusion line was connected with a 
canule (BraunuleR VasofixR 22 G), which was inserted into the portal 
vein to establish a continuous saline infusion (Q-40c at a height of 
50 em). The amount of saline needed to wash out the liver and make it 
suitable for transplantation was 250 ml. 
Prior to surgery the acceptor rat was anesthetized with 
ThalamonalR (a combination of DroperidolR 2.5mgjml and FentanylR 0.05 
mgjml) (JANSSEN Pharmac, Goirle, The Netherlands) intramuscularly at a 
dose of 0.3 ml per 100 g body weight, and 0.05 ml DepomycineR (GIST-
BROCADES, Delft, The Netherlands) was given subcutaneously. The board 
to which the rats were fastened was kept at a temperature of 370c. 
The abdomen was opened by a midline incision, and the aortic 
bifurcation including 1 em of the right iliac artery was dissected. 
A SilasticR (DOW CORNING, Brussels, Belgium) cannula (i.d. 0. 51 -
o.d. 0.94 mm) filled with a heparin solution (100 IU/ml) was fitted 
with a clamp and inserted into the right iliaca artery. Between the 
right and the left renal veins, the caval vein was freed of 
perivascular tissue. A section of the wall of the caval vein was 
isolated in a curved arterial clamp, and an aperture was cut in it. 
The cold liver graft was then placed in the abdominal cavity and the 
superior caval vein of the graft was to the recipient's caval vein 
anastomosed end-to-side with a running suture (9/0; DR 8 MirafilR 
blue, B.BRAUN, Melsungen, W-Germany). The portal vein of the graft 
was connected with the cannula, which was inserted into the right 
iliac artery and fixed in position with an encircling suture. In this 
way arterialization of the portal vein of the graft was achieved. 
Circulation was restored by releasing the clamp on the cannula. In 
some cases we evaluated changes in the morphology of the graft up to 
eight days after the transplantation. When an experiment required 
survival longer than 48 hr, the common bile duct of the graft was 
brought into the jejunum by the pull-through technique. 
After circulation of the graft was established, 0. 7 ml 
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bicarbonate (1000 mmol HC03-/l) was given intravenously every other 
hour during the first five post-operative hours ( 1) . The incision was 
closed with AutoclipsR (BEC'IDN DICKINSON, Parsipanny, USA). Most of 
the recipients developed severe coagulopathy, especially those given 
more then 500 mgjkg of galactosamine. Heating of the autoclips 
prevented blood loss from the abdominal muscles and the skin. Figure 
2 . 2 showes the schematic drawing of the auxiliairy partial liver 
transplantation. 
Fig. 2.2. 
Schematic drawing of the anatomy after APLT 
RK/LK = 
cv 
SCVG 
RIA 
PVG 
sc 
right/left kidney 
caval vein 
superior caval vein graft 
right iliac artery 
portal vein graft 
s Hastic cannula 
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Finally, 2.5 ml 5% glucose was given subcutaneously, and this 
was repeated five times during the first postoperative day. Twenty-
four hours after the operation, a second dose of DepomycineR was 
given. 
2.9. Parameters 
========== 
2.9.1. Biochemistry 
The levels of serum glutamic-oxaloacetic transaminase (SGOT), 
serum glutamic-pyruvic transaminase (SGPT), bilirubin, and glucose 
were detennined with standard laboratory equipment and techniques. 
The bromsulfophtalein measurements were performed in a 
colorimeter (BECKMAN, Brea, California, USA) at 540 nm. 
Antipyrine clearance was tested by high performance liquid 
chromatography (Beckman); Column (CHROMOPACKR, Middelburg, The 
Netherlands), no: 28811, packing material: 10 RP 18 with mobile phase 
of methanoljwater (55/45) at a flow rate of 2 ml/min (wave-lenght 254 
nm). 
The blood-gas measurements were perfonned with a automatic-
blood-gas analyser (AVL System 945R, Graz, Austria). 
2.9.2. Histology 
Samples were fixed in a 3.6% formaldehyde solution. The fixed 
tissue was dehydrated with ethanol and embedded in ParamatR. Sections 
were cut to a thickness of 3 micron and stained with hematoxylin-
eosin (HE). The Periodic Acid-Schiff (PAS) trichrome technique for 
polysaccharides and mucopolysaccharides was used in a few liver 
samples. 
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2.9.3. Function tests 
Bromsulfophtalein (BSP) clearance test: A dose of 8 mg BSP 
(BromthaleinR, E.MERCK, Da.DltStadt, W-Gennany) per 100 g body weight 
injected via the tail vein gave maximum storage capacity of the liver 
of WagjRij rats ( 5) . Blood was collected from the tip of the tail 2, 
5, 10, and 20 min after the injection of BSP. The animals were not 
continuously anesthetized during the test, and received only brief 
ether sedation for the tail cut. A 20-ul aliquot of the plasma sample 
was added to 5 ml 0.5 N NaOH in 0.9% NaCl. 
Antipyrine clearance test: Antipyrine in a dose of 100 mg per 
1000 g body weight was injected via the tail vein and blood was 
collected from the tip of the tail 1, 2, and 4 hr after the 
injection. Ether sedation was given during the tail cut, because it 
is known that a short ether anesthesia does not significantly change 
antipyrine kinetics in rats (23). To 100 ul plasma, 200 ul aceto-
nitril was added. After centrifugation the supernatant was stored at 
-2oOc. A 10 ul sample was chromatographed at room temperature. 
2.10. Statistical analysis 
The statistical significance of values obtained for effects on 
the survival rate were tested with the Kaplan-Meier method. This 
methods regards the cumulative survival times. The test starts with 
the total amount of used animals ( 100%) . The number of rats which 
succumbed are counted at various intervals (0-10, 10-24, 24-34, 
34-48, etc., up to and 168 hr) after galactosamine. The graph shows 
at each interval mentioned, the percentage of survival. The last 
interval for each survival course represents the percentage of 
surviving rats (28). 
The statistical significance of values obtained for effects on 
regeneration in terms of biochemical parameters detennined after a 
sub-lethal dose of galactosamine was tested with the Wilcoxon test 
(28). 
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CHAPI'ER 3. 
Dose-response relation of galactosamine in various rat strains 
============================================================== 
Before the investigation into the therapeutic effect of various 
treatment modalities on the course of experimentally induced acute 
hepatic failure could be started, a model was needed for evaluation 
of the selected forms of treatment. A variety of parameters are of 
importance in this respect, such as the dosage of the toxic substance 
to be used and the species and strain of the animals (3, 7,24,25). The 
dosage is particulary important, and by preference should give a 
death rate of 80 to 90% (LDgo). The dose-response relation of 
galactosamine and the survival rate were first investigated in two 
strains of rats, BN and Wag/Rij. Later, the sensitivity to 
galactosamine of the Lewis, WagjCpb, and Cpb:Wu strains was also 
assessed. All of the dose-response data are reported in this chapter. 
3. 1. Dose-respanse relation and survival rate of galactosamine 
in WagjRij and BN rats 
A dose responsec:relation for galactosamine and survival rate 
were estimated for the two strains of rats, WagjRij and BN, which 
have ·been used for many years in our laboratory for transplantation 
research. The serum levels of gluta~ic-oxaloacetic transaminase 
(SGOT), glutamic-pyruvic transaminase (SGPT), and bilirubin were 
.. . 
detennined in samples of blood taken from the tip of the tail 24 hr 
after the injection of galactosamine. 
Table 3.1 shows the survival rate and some liver function 
parameters for Wag/Rij and BN rats given various doses of 
galactosamine. The WagjRij rats had higher transaminase levels and 
shorter survival than the BN rats (p<0.001). Twenty-four hours after 
the administration of 250 mgjkg galactosamine, these levels were even 
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higher in WagjRij rats than in BN rats given a ten times higher dose 
of galactosamine. These findings show that unlike WagjRij 1 the BN rat 
strain is relatively insensitive to the toxic effect of galactosamine 
and therefore not suitable for use as a model for hepatic failure 
induced by this toxic agent. 
Table 3.1. 
Survival of WagjRij and BN rats after the indicated 
intraperitoneal doses of galactosamine. 
Rats d·GL (mg/kg) SGPT (u/L) SGOT (u/L) Bilirubin 
(umoi/L) 
Wag/Rij 0 52a ± 13 52±5 <2 
250 836 ± 815 1023± 946 3±1 
500 7433 ±2126 9457 ±2469 23±3 
1000 4215 ±470 9780± 1532 32± 13 
3000. 6428 + 1320 7865±690 39±8 
BN 0 27 ±3 56±9 <2 
1000 164 ±90 355 ± 195 <2 
3000 189 ±90 378 ± 167 <2 
Tail blood was collected 24 hr after the injection of 
galactosamine for the determination of soor I SGPI' I and 
serum bilirubin levels. 
a Mean value + S.D. 
b Number of rats that survived/total number of rats 
Survival 
4/4b 
4/4 
3/4 
0/4 
0/4 
4/4 
4/4 
4/4 
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Fig. 3.1. 
Percentage survival after intraperitoneal administration of 
the indicated doses of galactosamine 
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The dose-response relation for galactosamine and the survival 
rate for the WagjRij rat strain was estimated in more detail to 
establish the LOgo value. 
Figure 3.1 shows the relation between the dose of galactosamine 
and the survival rate in WagjRij rats. The LOgo dose was found to be 
1000 mg/kg. Figure 3. 2 shows the survival time distribution for 
Wag/Rij rats. The majority of the rats (64%) died 48 hr (second 
night) after receiving galactosamine. 
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Fig. 3.2. 
Course of survival time of rats which succumbed to 
the galactosamine poisoning (n=24). 
200 hr. 
3.2. Selection of a sub-lethal dose of galactosamine for Wag/Rij rats 
on the basis of liver function tests 
In a later stage of this study we wanted to investigate th,e 
effect of different treatment modalities on deteriorating .liver 
function. AS parameter for liver function we used the clearance of 
bromsulfophthalein (BSP) (5) and antipyrine. After a sub-lethal dose 
of galactosamine both of these functions deteriorated and then 
recovered within a few days without treatment (30,32). 
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Clearance of bromsulfophthalein (BSP) as reflected by 
plasma levels in WagjRij rats given 8 mg per 100 g body 
weight, 48 hr after injection of 125, 250, 400, and 
500 mg/kg galactosamine and saline. Blood was collected 
from the tip of the tail 2, 5, 10, and 20 min after the 
BSP injection (mean values~ S.D.). 
Galactosamine was given in various doses: 
125 mg/kg (n=5) ( •) 
250 mg/kg (n=5) (c) 
400 mg/kg (n=5) (.A) 
500 mg/kg (n=5) ( •) 
Control rats: saline (n=15) ( o). 
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For selection of the appropriate sub-lethal dose of 
galactosamine, the BSP clearance test was performed in rats 48 hr 
after the administration of 0, 125, 250, 400, and 500 mg/kg 
galactosamine. From previous experiments on the induction of a 
spontaneously reversible liver damage we knew that a dose of about 
500 mgjkg was the highest tolerable for WagjRij rats (6). 
Figure 3.3 shows the BSP elimination values (given as mean + 
S.D. in hours) determined 48 hr after administration of various doses 
of galactosamine. The lowest dose of galactosamine used (125 mgjkg) 
(clearance: half-life value (125 mgjkg) 5.8 ~ 1.0) did not change the 
normal elimination curve significantly. The other three doses gave 
longer clearance rates, i.e., 9.0 ~ 2.4, 17.2 ~ 6.0, and 15.7 ~ 4.7, 
for doses of 250, 400, and 500 mgjkg, respectively. The clearance 
rate was similar for 400 and 500 mgjkg galactosamine, but 
significantly shorter in rats given 250 mgjkg (p<0.01). On these 
grounds a dose of 400 mgjkg galactosamine was selected for the 
experiments on the deterioration of liver function. 
3. 3. Dose-response relation of galactosamine in Wag/Cpb, 
Cpb:Wu, and Lewis rats 
The mean survival time of the WagjRij rats after galactosamine 
intoxication was 48 hr. Because this interval proved to be rather 
short for the present study, we determined the sensitivity of three 
other rats strains to galactosamine toxicity, i.e. , WAG/Cpb, an 
inbred WAG strain with a genetic composition differing from that of 
WAG/Rij ( 3) ; Lewis, a strain which has been used by other 
investigators for the induction of acute hepatic failure (46-52, 84-
86); and Cpb:Wu, an outbred Wag strain (Wistar). 
Table 3. 2 shows the survival of these rats after various doses 
of galactosamine. The differences in their sensitivity to 
galactosamine are significant. The Wag/Cpb strain proved to be 
significantly less sensitive to galactosamine than the WagjRij strain 
and was therefore discarded. The sensitivity for galactosamine of the 
Cpb:Wu strain was comparable to that of the WagjRij strain. Since the 
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Cpb:Wu is an outbred strain, it is suitable for experiments with 
cytosol but not for experiments involving transplantation of isolated 
hepatocytes . 
The sensitivity of the Lewis strain was comparable to that of 
the Wag/Rij strain. 
Figure 3. 4 shows the survival-time distribution for the Lewis 
and Cpb:Wu strains and, for comparison, the WagjRij strain. The Lewis 
rats showed the same mortality pattern as the Wag/Rij rats. Most of 
the Cpb:Wu rats (73%) died 72 hr after galactosamine administration, 
i.e., one day later than the death of most (64%) of the WagjRij rats. 
For the experiments on liver function recovery we selected a 
dose of 1500 mg/kg galactosamine for the Lewis and 1000 mg/kg for the 
Cpb: Wu rats . Figure 3 . 5 shows the course of antipyrine clearance in 
the Cpb: Wu strain after a sub-lethal dose ( 1000 mgjkg) of 
galactosamine, and gives the course of the half-life values of 
antipyrine in the Lewis strain given a sub-lethal dose ( 1500 mgjkg) 
of galactosamine. 
Table 3.2. 
Survival rate and the SGOI' (mean, U/1) levels in four rat strains 
(WagjCpb, Cpb:Wu, Lewis, Wag/Rij) after various doses of 
galactosamine (0, 500, 1000, 2000, and 3000 mg/kg). 
Wag/Cpb Cpb:Wu Lewis 
d·GL mg/kg Survival SGOT (u/L) Survival SGOT (u/L) Survival SGOT (u/L) 
0 4/4a 94b 4/4 40 4/4 117 
500 4/4 740 4/4 840 4/4 1142 
1000 3/4 954 1/4 1641 4/4 820 
2000 4/4 1042 1/4 3355 1/4 1640 
3000 4/4 1317 0/4 2578 0/4 2455 
Tail blood was collected 24 hr after the injection of 
galactosamine for the determination of SGOI' levels. 
a Number of rats which survived/total number of rats 
b Mean values 
Wag/Rij 
Survival SGOT (u/L) 
4/4 52 
3/4 9457 
0/4 9780 
0/4 7865 
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Course of the survival time of animals which succumbed to 
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Course of antipyrine half-life values in Cpb:Wu rats after 
administration of 1000 mgjkg galactosamine and Lewis rats after 
administration of 1500 mg/kg galactosamine (values are mean and 
standard deviation) . 
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3.4. Conclusions 
The results of the studies in rats of the BN, WagjRij, Wag/Cpb, 
Cpb:Wu, and Lewis strains showed that BN and Wag/Cpb were not 
sensitive to galactosamine, using the survival as parameter. Further 
analysis of the survival-time data for the WagjRij, Cpb:Wu, and Lewis 
strains showed that the majority (ca. 60%) of the WagjRij and the 
Lewis rats died 48 hr after galactosamine administration and 73% of 
the Cpb: Wu rats at 72 hr. 
For the survival studies the lethal dosage of galactosamine 
chosen for WagjRij rats was 1000 mg/kg. For the liver function 
studies in the WagjRij, Lewis, and Cpb:Wu strains the sub-lethal dose 
was put at 400, 1500, 1000 mg/kg galactosamine, respectively. 
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CHAPTER 4 
Effects of different treatment modalities 
on the survival rate of WagjRij rats 
Positive effects of transplantation of viable isolated 
hepatocytes, administration of homogenate or cytosol of no=al or 
regenerating liver tissue, or administration of cell-free supernatant 
of hepatocyte cultures on the survival rate in galactosamine 
hepatitis have been reported, as discussed in the introduction of 
this thesis (2,15,20,46-52,63,64,83-86,90). These investigators 
considered that the evidence pointed strongly to the existence of a 
trophic factor that stimulates regeneration in such a way that 
significantly more rats survive after the administration of a 
hepatotoxic substance in a dosage causing so much cell injury that 
the majority of the animals die (LDgo). We investigated various 
therapeutic modalities to evaluate their effect on the survival rate 
of rats suffering from acute hepatic failure. In all of the 
experiments mentioned in this chapter, 1000 mgjkg galactosamine was 
administered intraperitoneally to induce lethal damage to the liver. 
4.1. Treatment with hepatocytes injected into the abdominal cavity 
The effect of transplantation of intact hepatocytes on the 
survival rate of rats after the intraperitoneal administration of a 
lethal dose of galactosamine (1000 mgjkg) was investigated first. At 
various intervals ( 6, 12, and 24 hr) after administration of 
galactosamine, viable hepatocytes (40x106) were injected into the 
abdominal cavity. Different rats were used for each interval. A group 
of control rats received the same volume of medium alone 24 hr after 
the injection of galactosamine. 
Figure 4. 1 shows the survival-time distribution for rats given 
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40x106 isogenically isolated hepatocytes 6, 12, or 24 hr after the 
galactosamine injection. No significant differences were observed 
between the groups given hepatocytes and the controls which received 
only saline. 
4.2. Treatment with hepatocyte fractions 
4.2.a. The effect of the administration of crude homogenate prepared 
from normal liver tissue on the survival rate after galactosamine 
intoxication was studied. Crude homogenate was injected intra-
peritoneally into all rats in the experimental group (n=12) 12 and 
24 hr after the injection of galactosamine. Control rats received 
only the same volume of saline administered twice after the 
galactosamine injection (n=7). 
4.2.b. The same experiment was performed with crude homogenate of 
regenerating liver tissue. One group of rats (n=15) was treated twice 
( 12 and 14 hr after galactosamine poisoning) with crude homogenate 
prepared from liver tissue of donor rats which had undergone a 70% 
hepatectomy 72 hr earlier. The interval of 72 hr was chosen on the 
basis of the results of the study performed by Terblanche et al.(88). 
A second group (n=13) was treated with crude homogenate prepared from 
liver tissue of donor rats which had undergone a 70% hepatectomy 24 
hr earlier. The interval of 24 hr was chosen on the basis of the 
findings made in several studies performed in rats (41,53,61,64). 
Contr'9l rats received only the same volume of saline administered 
twice after the galactosamine injection (n=6). 
Figure 4.2 shows the survival-time distribution for the rats 
given a crude homogenate of normal tissue (group B), a crude 
homogenate of regenerating liver tissue prepared 72 hr after partial 
hepatectomy (group C) or 24 hr after partial hepatectomy (group D) , 
in all cases 12 and 24 hr after the injection of galactosamine. Group 
A, the control group, received saline after the galactosamine 
injection. 
A significant difference (p 0. 01) was found between the group 
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treated with crude homogenate (C and D) of regenerating liver tissue 
and the group treated with saline instead of homogenate. All of the 
treated rats died during the second day. 
4. 2. c. The same experiment was perfonned with cytosols of nonnal 
liver tissue and regenerating liver tissue. Figure 4.3 shows the 
survival-time distribution for rats given the cytosol at various 
intervals after the galactosamine injection. Cytosol prepared from 
regenerating liver tissue sampled 24 hr after a 70% partial 
hepatectomy, was injected 12 and 24 hr after the galactosamine 
injection (group B). In group C cytosol was administered 12 and 24 hr 
after galactosamine but the cytosol had been prepared 72 hr after 70% 
hepatectomy. Group D received cytosol of normal liver tissue 12 and 
24 hr after galactosamine administration. Group A (the controls) 
received only the same volume of medium 12 and 24 hr after 
galactosamine. In this experiment none of the treatment modalities 
improved the survival rate significantly. 
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Fig. 4.1 A-D. 
Results obtained with hepatocytes administered intraperitoneally I 
expressed as the distribution of survival times of rats given 
1000 mgjkg galactosamine. 
A: Rats 
B: Rats 
C: Rats 
D: Rats 
given saline 24 hr after galactosamine (n=12) 
given 40 x 106 hepatocytes 24 hr after galactosamine (n=17) 
given 40 x 106 hepatocytes 12 hr after galactosamine (n=10) 
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Fig. 4.2 A-D. 
Results obtained with liver homogenate injected intraperitoneally, 
expressed as the distribution of survival times of rats after 
administration of 1000 mgjkg galactosamine. 
A: Rats given saline 12 and 24 hr after galactosamine (n=13) 
B: Rats given crude homogenate of normal liver tissue 12 and 
24 hr after galactosamine (n=12) 
C: Rats given crude homogenate of regenerating liver tissue 
prepared 72 hr after 70% hepatectomy in the donor and 
administered 12 and 24 hr after galactosamine (n=15) 
D: Rats given crude homogenate of regeneratiri.g liver tissue 
prepared 24 hr after 70% hepatectomy in the donor and 
administered 12 and 24 hr after galactosamine (n=13) 
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4.3. Treatment with cell-free supernatant 
The effect was investigated of the administration of cell-free 
supernatant prepared from liver cell cultures 24 hr after plating, on 
the survival rate after an injection of galactosamine. One group of 
rats (A) was given intraperitoneally 2 ml of this culture medium 12 
and 24 hr after galactosamine poisoning. The control group (B) 
received the same volume of medium alone at the same time. 
Figure 4.4 shows the survival-time distribution for rats given 
cell-free supernatant from hepatocyte cultures. No significant 
difference was found between the group treated with cell-free 
supernatant and the group given normal medium. 
4.4. Treatment with hepatocytes implanted in the spleen 
Implantation of liver cells in the spleen 24 hr after 
administration of 1000 mg/kg galactosamine led to severe bleeding 
problems. All rats died within three hours after receiving 
hepatocytes (Fig. 4. 5 A) . Injection of saline into the spleen 24 hr 
after 1000 mg/kg galactosamine had no influence on the normal 
survival rate (Fig. 4.5 B). Problems of the same kind developed when 
we injected hepatocytes in the spleen _12 hr after galactosamine 
administration. All rats died within five hours after implantation 
(Fig, 4. 5 C). Implantation of cells in the spleen 6 hr after 
galactosamine did not lead to coagulation problems but the rats still 
died sooner (Fig.4.5 D) than those given saline and hepatocytes in 
the spleen (Fig.4.5 E). There was no mortality after implantation of 
hepatocytes in the spleen of normal rats. Implantation in the spleen 
has also been reported by others to give rise to severe clotting 
disorders (54) . 
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Fig. 4.3 A-D. 
Results of treatment with cytosol administered intraperitoneally, 
expressed as the distribution of survival times of rats after 
administration of 1000 mgjkg galactosamine. 
A: Rats given saline 12 and 24 hr after galactosamine (n=7) 
B: Rats given cytosol of regenerating liver tissue prepared 24 hr 
after 70% hepatectomy in the donor and administered 12 and 24 hr 
after galactosamine (n=15) 
C: Rats given cytosol of regenerating liver tissue prepared 72 hr 
after 70% hepatectomy in the donor and administered at 12 and 
24 hr after galactosamine (n=15) 
D: Rats given cytosol of normal liver tissue 12 and 24 hr after 
galactosamine (n=15) 
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Fig. 4.4 A and B. 
Distribution of survival times of rats treated intraperitoneally with 
cell-free supernatant after 1000 mgjkg of galactosamine. 
A: Rats given normal culture medium 12 and 24 hr after 
galactosamine (n=10) 
B: Rats given cell-free supernatant prepared from liver cell 
cultures 24 hr after plating of cells, and administered 12 and 
24 hr after the galactosamine injection (n=10) 
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Fig. 4.5 A-E. 
Results of implantation of hepatocytes in the spleen, expressed as 
the distribution of the survival times of rats given 1000 rngjkg 
galactosamine. 
A: Rats given 20-30x1o6 hepatocytes injected into the spleen 24 hr 
after galactosamine (n=10) 
B: Rats given saline injected into the spleen 24 hr after 
galactosamine (n=10) 
C: Rats given 20-30x106 hepatocytes injected into the spleen 12 hr 
after galactosamine (n=lO) 
D: Rats given 20-30xlo6 hepatocytes injected into the spleen 6 hr 
after galactosamine (n=10) 
E: Rats given saline injected into the spleen 6 hr after 
galactosamine (n=lO) 
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4.5. Conclusions 
Treatment with syngenically isolated hepatocytes did not 
improve the survival rate of rats suffering from acute liver failure 
induced by galactosamine. The same holds for the rats treated with 
hepatocyte fractions and cell-free supernatant. In the rats treated 
with hepatocytes implanted in the spleen, the surgical and 
implantation procedures had a lethal effect on the animals . The 
bleeding problems encountered · after implantation of the hepatocytes 
were severe. Another problem was that some of the hepatocytes entered 
through the lienal vein and reached the liver, where they caused a 
severe portal hypertension as noticed during autopsy. 
The distribution of the survival times of the control rats in 
the different treatment groups did not differ significantly. Rats 
given galactosamine only were compared with the rats treated with one 
of the modalities. Of the 42 control rats, 62% died during the second 
night after the galactosamine injection; 74% of the 42 rats given 
isolated hepatocytes died during the second day after galactosamine; 
78% of the 40 rats given homogenate, 60% of the 45 rats treated with 
cytosol, and 90% of the 10 rats treated with cell-free supernatant 
also died on the second day. 
Transplantation of viable hepatocytes led to a mean survival 
time of about 48 hr after the administration of galactosamine, which 
is rather short. This interval must be sufficiently long to allow 
expression of the influence of the treatment on the process of 
galactosamine-induced liver degeneration. However, it must be kept in 
mind here that hepatocytes transplantated between 6 and 12 hr after 
galactosamine administration increase the risk of damage due to 
galactosamine or its metabolic consequences, as will be discussed in 
the next chapter. 
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CHAPTER 5 
Metabolite Deficit Period 
========================= 
Galactosamine has a patho-physiological effect caused by its 
trapping of the essential co-factor uridine triphosphate (UTP) (32). A 
marked decrease in UTP is accompanied by an inhibition of RNA and 
protein synthesis and other uracil dependant biosynthesis ( 7 6, 77) , 
which leads to organelle injury and cell necrosis. 
Decker and Keppler ( 14) introduced the term metabolite .deficit 
period to denote a well-defined interval of uridine deficiency, in 
the present case the interval between galactosamine and uridine 
administration. Farber and co-workers (18) reported that injection of 
uridine at the same time as galactosamine prevented the hepatic 
failure caused by galactosamine. Uridine given up to 3 hr after 
galactosamine reversed the signs of hepatic failure, but was unable 
to do so when given a13 late as 6 hr. 
In connection with the short mean survival time ( 48 hr) of rats 
given galactosamine, which made it difficult to assess the,€ffects of 
the therapy on survival, we wanted to lengthen the period after 
galactosamine injection. The interval between transplantation of 
hepatocytes and the time of. death must sufficiently long to permit 
observation of the recovery process involved. Prolongation of the 
effective period of the injected hepatocytes must be obtained .by 
transplantating the cells sooner, but that might expose them to 
damage arising from the galactosamine-induced UTP deficiency. As 
reported (34,15) the time when uridine should be given is 6 hr after 
galactosamine reversal of the liver damage is not obtained (14) but 
the negative effects on the transplanted hepatocytes are avoided. as 
reported. This chapter deals with the studies performed to determine 
the dosage of uridine capable of preventing the death of the injected 
hepatocytes, as well as the most favorable time to apply it, in order 
not to influence the liver damage. 
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5.1. Determination of an effective metabolite deficit period 
Administration of galactosamine in a dose of 1000 mg/kg, 
followed by injection of saline, results in a survival rate of 10 
percent (Table 5. 1. united controle groups: 2 out of 20 rats 
survived) . This is in accordance with the results in previous 
experiments, in order to determine the LDgo. Administration of 
uridine in various doses together with galactosamine reduced the 
mortality in a dose-dependent fashion (18,32). The lowest dose of 
uridine that improved the survival rate was 500 mgjkg (on a molecular 
basis 11% of the dose of galactosamine (see Table 5.1). The other 
doses of uridine used in the study were 125, 250, 1000, and 2000 
mgjkg uridine. Uridine improved the survival rate significantly when 
given up to and including 12 hr after galactosamine, but not when 
administrated after an interval of 18 hr. The duration of the 
interval between administration of the two compounds did not 
influence the minimal effective dose of uridine; for all dosages, 500 
mgjkg uridine was the lowest dose to give significant enhancement of 
the sw:vival rate. Figure 5.1 shows the percentage of rats which 
survived on each of the days after galactosamine injection. The 
percentage of rats given galactosamine and saline or galactosamine 
and uridine are presented separately. The majority of the rats in 
both groups died within 48 hr, which is in accordance with the 
earlier findings. No differences were found in the survival rate for 
successive periods between the saline and the uridine groups after 
galactosamine. Thus, the administration of uridine increased the 
survival rate but did not create a longer available therapeutic 
period. 
Uridine was administered in doses up to 2000 mgjkg. The highest 
dose did not influence the SGOI' level (Table 3.1: 52.::_ 7 U/1, n=7) in 
the untreated control rats, where it did not differ from the levels 
(59 .::_ 6 U/1, n=8) measured in the rats given galactosamine and 2000 
mgjkg uridine. Administration of uridine led to a dose- and interval-
dependent depression of the SGOT levels after galactosamine 
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administration (Table 5.2). Uridine given 12 hr after galactosamine 
significantly increased the survival but did not no.nnalize the SGOI' 
levels. Comparison of the SGOI' values in all of the rats which 
survived, with all of the rats which death occured within 48 hr after 
galactosamine injection and with all rats which died later than 48 hr 
after galactosamine administration showed for the first group a 
significantly lower value. (4179 ~ 3055 U/1, n=35; 11378 + 3357 U/1, 
n=18; 11453 ~ 3139 U/1, n=11 (resp.; mean,~ S.D.)). 
The effect of uridine on the serum bilirubin level was 
comparable to that observed for SGOI' (Table 5. 3) . For the individual 
rats a significant correlation (p<0.001) was found between the SGOI' 
and bilirubin values. Comparison of the bilirubin values of all 
surviving rats with those of all the rats which died before or after 
48 hr also showed for the first group a significant difference (22 ~ 
18 umol/1; 58+ 17 umol/1; 50~ 16 umol/1 (resp.; mean~ S.D.)). 
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Table 5.1. 
Survival rate of WagjRij rats after intraperitoneal administration of 
1000 mg/kg galactosamine and various doses of uridine, expressed as 
the number of survivors/total number of rats. 
Uridine Interval between d·GL and uridine administration 
(mg/kg) 0 6 12 18 24 (hours) 
Saline 1/4 0/4 0/4 1/4 0/4 2120 1 
125 1/4 2/4 - - - II-
250 0/4 1/4 - - -
500 3/4 4/4 3/4 1/4 0/4 
1000 3/4 4/4 2/4 0/4 2/4 
2000 4/4 4/4 3/4 1/4 0/4 
10/12 12/12 8/12 2/12 2/12 
<0.01 <0.01 <0.01 N.S. N.S. +-P 
At various intervals after galactosamine injection, uridine or saline 
was injected intraperitoneally (0, 6, 12, 18, and 24 hr). Uridine was 
given in various doses ( 125 up to and including 2000 mg/kg) . 
p: level of significance between the pooled data of the control 
(saline) groups and the pooled data of the groups, which received the 
three highest doses of uridine (500, 1000, 2000 mg/kg) for the 
successive intervals. 
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Table 5.2. 
Serum glutamic-oxalocetic transaminase (SGOI') levels (mean, U/1) 
detennined after the injection of 1000 mg/kg galactosamine and 
various doses of uridine. 
Uridine Interval between d·GL and uridine administration 
(mg/kg) 0 6 12 (hours) 
Saline 8350 9780 10693 9608 I 
125 9194 8034 -
250 12384 9235 -
500 5618 6439 6641 
1000 4101 5481 10950 
2000 377 1330 9889 
3365 4417 9160 
<0.001 <0.001 N.S. ~p 
At various intervals after galactosamine injection, uridine or saline 
was injected intraperitoneally (0, 6, and 12 hr). Uridine was given 
in various doses ( 125 up to and including 2000 mgjkg). Each group 
comprised 4 rats. 
p: level of significance between the pooled data of the control 
(saline) groups and the pooled data of the groups, which received the 
three highest doses of uridine (500, 1000, 2000 mgjkg) for the 
successive intervals. 
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Fig. 5.1. 
Distribution of the survival times of the rats which died after an 
intraperitoneal injection of galactosamine. 
Group A: rats given saline at the indicated intervals after 
galactosamine (see Table 3 . 1 : 18 non-survivors out of 20 rats) . 
Group B: rats given uridine at the indicated intervals after 
galactosamine (see Table 3.1: 38 non-survivors out of 76 rats). 
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Table 5.3. 
Serum bilirubin levels (mean, umol/1) determined after the injection 
of 1000 mg/kg galactosamine and various doses of uridine. 
Uridine Interval between d·GL uridine administration 
(mg/kg) 0 6 12 (hours) 
Saline 1 41 32 70 48 I 
125 59 37 -
250 63 32 -
500 26 32 37 
1000 14 40 54 
2000 <2 11 38 
14 27 43 
<0.01 <0.05 N.S. +--P 
At various intervals after galactosamine injection, uridine or saline 
was injected intraperitoneally (0, 6, and 12 hr). Uridine was given 
in various doses (125 up to and including 2000 mgjkg). Each group 
comprised 4 rats. 
p: level of significance between the pooled data of the control 
(saline) groups and the pooled data of the groups, which received the 
three highest doses of uridine (500, 1000, 2000 mgjkg) for the 
successive intervals. 
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5. 2. Conclusions 
Uridine can reverse the effects of galactosamine but using 
survival as criterion we were unable to select a dose of uridine that 
would prevent hepatocellular death when given at the same time as 
galactosamine but not when given 6 hr after galactosamine. The 
maximum interval between administration of the two compounds in which 
uridine still significantly enhanced the survival rate lay between 12 
and 18 hr after galactosamine injection. This interval is much longer 
than those reported by other investigators (14,18,32, 76, 77). Those 
authors used biochemical and histological parameters as criterion for 
liver cell injury, in particular enzyme leakage (SGOI'), whereas we 
used the survival rate, which proved to be a more suitable parameter 
than enzyme leakage to define the duration of the period in which the 
toxin induced hepatic lesions are potentially reversible. Use of the 
SGOT values gives a shorter interval before the stage of 
irreversibility is reached than use of the survival rate does. 
It is evident that with the present model of lethal 
galactosamine hepatitis and the use of uridine, experimental therapy 
should not be started earlier than 18 to 24 hr after the injection of 
galactosamine. Otherwise it will not be clear whether enhanced 
survival is due to a stimulation of the regeneration or to a 
reduction of the degenerative action of the galactosamine. 
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CHAPTER 6 
Effects of different treatment modalities on 
deteriorating liver function in Wag/Rij rats 
============================================= 
Chapter 4 dealt with the effect of transplantation of isolated 
hepatocytes and hepatocyte fractions and cytosol on the survival rate 
rats suffering from galactosamine-induced acute liver failure. 
Transplantation of syngenic viable isolated hepatocytes and 
hepatocyte fractions failed to improve the survival rate. It is 
possible that the implanted hepatocytes improved the function of the 
affected liver, but that the interval between transplantation of the 
hepatocytes and the moment of the animal's death was too short to 
allow the transplanted hepatocytes to improve survival by restoration 
of the function of the damaged host liver. Administration of uridine 
failed to lenghten this period, as reported in Chapter 5 (31,92). 
It is also possible that the dose of galactosamine we used (1000 
mgjkg) induces irreversible hepatic injury that cannot be reversed by 
any treatment. The reversibilty of damage to liver cells, as in a 
fulminant hepatic failure, is still a matter of debate. 
In the studies discussed in this chapter we investigated the 
effect of transplantation of hepatocytes and cytosol on regeneration 
of liver tissue after a sub-lethal dose of galactosamine. Here, 
values given by aspecific liver function tests were used as parameter 
instead of the of survival rate. 
6.1. Treatment with hepatocytes injected into the abdominal cavity 
Isolated hepatocytes (40x106) were injected into the abdominal 
cavity 24 hr after the administration of 400 mg/kg galactosamine. The 
cell suspension (20x1o6 per ml) was injected via a teflon catheter to 
prevent damage to the cells and decrease the risk of injuring the 
L~testines. The BSP elimination test was performed in rats 1,2,3,4,6 
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and 8 days after galactosamine injection. The BSP elimination test 
was perfonned in the treated rats was perfonned 1, 2, and 3 days 
after implantation of the liver cells, i.e., 2, 3, and 4 days after 
galactosamine. Only one test was perfonned in each rat, including the 
control rats given saline instead of galactosamine. Sham-treated rats 
received only the same volume of medium 24 hr after administration of 
galactosamine. 
Figure 6.1 shows the half-life values for BSP. The value found 
in sham rats given medium without hepatocytes was significantly 
(p<0.01) enhanced to the same extent (16.5 ..!. 4.3 and 16.4 ..!. 5.2, 
respectively) on days 1 and 2 after galactosamine injection relative 
to the control rats. On days 3 and 4 the half-life values declined in 
sham rats (from 13.6..!. 6.2 to 12.1 ..!. 5.4) but still differed 
significantly (p<0.01) from the values of the control rats. On days 6 
and 8 (7.2..!. 0.6 and 5.7..!. 0.2, respectively) the half-life values 
had returned to nonnal. The elimination rate of BSP in rats, in which 
isolated hepatocytes were implanted in the abdominal cavity one day 
after galactosamine injection, did not differ significantly from the 
elimination rate found for sham rats treated with medium only (day 2: 
16.4..!. 1.4; day 3: 12.3..!. 1.1; day 4: 9.2..!. 2.4). It is noteworthy 
that the standard deviation of the half-life values within each group 
increased substantially after the injection of galactosamine. 
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Half-life values for serum plasma bromosulfophthalein (BSP) in rats 
treated with isolated hepatocytes after receiving 400 mg/kg 
galactosamine intraperitoneally. 
Isolated syngenic hepatocytes were injected into the abdominal cavity 
24 hr after the administration of galactosamine. The half-life values 
of BSP for the hepatocyte-treated rats were determined 2, 3, and 4 
days after galactosamine. The half-life values for the control rats 
were determined 1, 2, 3, 4, 6, and 8 days after galactosamine. 
o : saline medium BSP clearance (control rats) 
o: galactosamine medium BSP clearance (sham rats) 
c : galactosamine hepatocytes BSP clearance 
* : number of rats used 
-: mean value..:!:. S.D. 
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6.2. Treatment with cytosol 
Cytosol was injected intraperitoneally 24 hr after the injection 
of 400 mg/kg galactosamine. The same volume of medium was injected 
intraperitoneally into the sham-treatment rats. The antipyrine 
elimination test was performed 24 and 48 hr after the injection of 
cytosol or injection medium (48 and 72 hr after galactosamine). Only 
one test was performed in each rat. The antipyrine elimination test 
was also performed in control rats given saline instead of 
galactosamine. 
Figure 6 . 2 shows the half-life values for antipyrine. In sham 
rats, given the medium alone instead of cytosol, these values were 
significantly elevated 48 hr after injection of galactosamine (from 
1.45 ~ 0.29 to 2.93 ~ 1.38) (p<0.01). The antipyrine elimination rate 
in rats given cytosol intraperitoneally 24 hr after galactosamine did 
not differ significantly from the values of the sham rats. 
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Fig. 6.2. 
Half-life values for serum antipyrine in rats treated with cytosol 
after receiving 400 mg/kg galactosamine intraperitoneally. 
The cytosol was injected intraperitoneally 24 hr after the 
administration of galactosamine. The half-life values for antipyrine 
for the cytosol-treated rats and control rats were determined 48 and 
72 hr after galactosamine injection. 
o: saline medium 
• : galactosamine medium 
c: galactosamine cytosol 
* : number of rats 
mean value + S.D. 
antipyrine (control rats) 
antipyrine (sham rats) 
antipyrine 
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6.3. The fate of hepatocytes injected into the peritoneal 
cavity or the spleen 
Earlier experiments having shown that improvement of the 
survival rate would not be obtained with any of the treatment 
modalities under study and even no improvement of the deteriorating 
liver function was accomplished. This might been explained by the 
early death of the injected hepatocytes. 
Rats given hepatocytes in the abdominal cavity were killed 6 hr 
after the injection of the cells. At autopsy, a few hard white clumps 
of necrotic hepatocytes were found in the abdominal cavity (Fig.6.3). 
Samples of the same hepatocyte cell suspension were cultured, and the 
resulting colonies showed good growth (Fig.6.4). 
Rats in which hepatocytes were implanted in the spleen were 
killed after various intervals up to 16 months. Light-microscopical 
examination of the spleen tissue showed hepatocytes with a normal 
appearance scattered throughout the organ (Figs.6.5 and 6.6) 
(56-58,94). After the implantation procedure we noticed that some of 
the hepatocytes injected into the spleen found their way through the 
splenic vein to the liver. Histologically, the liver tissue showed 
small islands of healthy aggregated hepatocytes (Fig.6.7). 
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Fig. 6.3. 
Clumps of necrotic hepatocytes found in the abdominal cavity 
6 hr after intraperitoneal injection of the hepatocytes. 
The trypan blue exclusion test was applied to assess viability. 
Fig. 6.4. 
Phase contrast micrograph of a 24-hr-old cell culture of an isolated 
hepatocyte sample. x 400. 
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Fig. 6.5. 
Light-microscopical section of the spleen with healthy hepatocytes in 
the spleen 16 months after the implantation. PAS. x 150. 
Fig. 6.6. 
Light-microscopical section of the spleen with glycogen granules in 
the cytoplasm of hepatocytes 16 months after implantation. 
PAS. X 600. 
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Fig. 6. 7. 
Light-microscopical section of the liver with hepatocyte island of 
aggregated hepatocytes 48 hr after implantation of hepatocytes in the 
spleen. HE. x 150. 
6 . 4. Treatment by implantation of hepatocytes in the spleen 
Isolated hepatocytes (20-30x106) were implantated in the spleen 
in a cell suspension (40xlo6 cells per ml) which was injected 24 hr 
after the intraperitoneal injection of 400 mgjkg galactosamine. The 
same volume of medium alone was injected into the spleen of sham rats 
24 hr after galactosamine injection. The antipyrine clearance test 
was performed 24 and 48 hr after the implantation of the cells or 
injection of the medium, i.e., 48 and 72 hr after the injection of 
galactosamine. Only one test was performed in each rat. Figure 6.8 
shows the antipyrine half-life values in sham rats given medium alone 
and rats treated with isolated hepatocytes in the spleen. The half-
life values of the sham rats were significantly higher at 48 hr (1.65 
.!. 0.19 to 4.49 + 2.32) than those of the control rats given 
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galactosamine alone (p<O.Ol). At 72 hr (2.29 .!. 0.59) the half-life 
values declined, but still differed significantly from those of the 
control rats (p<O. 05) . The elimination rate of antipyrine in rats 
given isolated hepatocytes injected into the spleen 24 hr after 
galactosamine did not differ significantly from the values obtained 
in sham rats given only medium. 
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Half-life values for serum antipyrine in rats given isolated 
hepatocytes in the spleen after 400 mgjkg galactosamine injected 
intraperitoneally. 
Isolated syngenic hepatocytes were implanted in the spleen 24 hr 
after the administration of galactosamine. The half-life values for 
antipyrine in the hepatocyte-treated rats and control rats were 
determined 48 and 72 hr after galactosamine injection. 
o: saline medium antipyrine (control rats) 
• : galactosamine medium antipyrine (sham rats) 
c: galactosamine hepatocytes antipyrine 
*: number of rats 
---: mean value + S.D. 
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Here again the half-life values fluctuated considerably after the 
injection of galactosamine, as had been observed for BSP clearance 
and antipyrine clearance. 
6.5. Conclusions 
For the studies reported in this chapter a spontaneously 
reversible degree of hepatic failure was induced. Implantation of 
syngenic isolated hepatocytes and cytosol did not accelerate the 
recovery of the deteriorating liver function, as measured by the BSP 
and. antipyrine tests. Determination of the viability of hepatocytes 
implanted in different regions showed that those in the abdominal 
cavity died very soon after implantation, unlike those in the spleen, 
which proliferated up to 16 months 1 (19,21,35,36,55-58,94). In the 
view of the present findings it seems unlikely that hepatocytes can 
be expected to have a stimulating effect within the short period of 
survival after abdominal injection. 
The results of these studies indicate that irreversibility of 
the injury does not explain the poor survival, because a sub-lethal 
dose was used. Furthermore, we found comparable and substantial 
variation of the degree of deterioration of the liver function after 
the injection of galactosamine. The increase of the half-life values 
was the same in the BSP and the antipyrine clearance tests . The 
variation of the . clearance-test values within each group was not 
significantly greater than the variation of the values within each 
session (p>O. 05) . Marked variability of galactosamine-induced liver 
injury was also found by Tabata (87). 
The results reported in this chapter concerning the influence of 
implanted hepatocytes on the process of recovery of liver function 
are similar to those obtained for the survival rate after treatment 
of the rats with hepatocytes or hepatocyte fractions (Chapter 4). We 
were unable in either case to reverse the hepatocellular damage 
induced by galactosamine. 
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CHAPTER 7 
Effects of transplantation of hepatocytes and cytosol on 
deteriorating liver function in 
Lewis and Cpb:Wu rats 
======================================================== 
As discussed in the preceding chapters, we were unable to 
reproduce the favorable effect of hepatocyte transplantation in the 
presence of acute hepatic failure on animal survival reported by 
others (46-52,62,84-86). To be certain that our negative results were 
not due to a difference in strain sensitivity, we repeated the 
studies in other strains as used by other authors (24,25,46-52, 
84-86). The effects of the same treatment modalities on deteriorating 
liver function were investigated in an inbred strain (Lewis rats) and 
an outbred strain (Cpb:Wu rats) given a sub-lethal dose 
galactosamine. 
7.1. Lewis rats treated by implantation of hepatocytes in the spleen 
Isolated hepatocytes (20-30x106) were implanted in the spleen 
24 hr after intraperitoneal injection of 1500 mgjkg galactosamine, 
which is a sub-lethal dose, as reported in Chapter 3. The same volume 
of medium was injected into the spleen of the control rats as sham 
treatment. The antipyrine clearance test was perfonned 24 and 48 hr 
after implantation of the cells or injection of medium, i.e., 48 and 
72 hr after the injection of galactosamine. Only one test was done in 
each rat. The antipyrine elimination test was also perfonned in the 
control rats given saline instead of galactosamine. 
Figure 7.1 shows the half-life values of antipyrine. In the 
rats given medium instead of hepatocytes, the half-life values 
improved significantly (1.82 + 0.24 to 4.23.:!:. 1.18) 48 hr after 
galactosamine injection (p<0.01). The half-life values of antypirine 
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in rats which received isolated hepatocytes implanted in the spleen 
24 hr after galactosamine injection, increased compared with the 
values of the rats given medium (4.44 2. 0. 7 compared with 4.03 2. 1.3). 
Eight animals died within 3 hr after implantation of hepatocytes in 
the spleen. The autopsy results showed severe bleeding in the 
intestine, possibly due to severe portal hypertension. 
7.2. Lewis rats treated with cytosol 
Cytosol was injected intraperitoneally 24 hr after injection of 
1500 mg/kg galactosamine. The same volume of medium was injected into 
sham rats 24 hr after galactosamine. The antipyrine clearance test 
was performed 24 and 48 hr after the injection of cytosol or medium, 
i.e. , 48 and 72 hr after galactosamine. Only one test was done in 
each rats. The antipyrine elimination test was also performed in the 
control rats. 
Figure 7.2 shows the half-life values of antipyrine. The values 
determined in sham rats given medium instead of cytosol improved 
significantly (1.83 2. 0.3 to 3.41 2. 0.8) 48 hr after galactosamine 
injection (p<O. 01). The antipyrine elimination rate in rats given 
cytosol intraperitoneally 24 hr after galactosamine did not differ 
significantly from the values obtained in the sham rats given medium. 
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Fig. 7 .1. 
Half-life values for serum antipyrine in Lewis rats treated by 
implantation of isolated hepatocytes in the spleen, after 
1500 mgjkg galactosamine intraperitoneally. 
Isolated syngenic hepatocytes were implanted in the spleen 2 4 hr 
after the administration of galactosamine. The values for antipyrine 
in the hepatocyte-treated rats and control rats were dete.nnined 48 
and 72 hr after galactosamine injection. 
o : saline medium antipyrine (control rats) 
e: galactosamine medium antipyrine (sham rats) 
o: galactosamine hepatocytes antipyrine 
* : number of rats 
-: mean value + S.D. 
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Half-life values for serum antipyrine in Lewis rats treated with 
cytosol, after receiving 1500 mgjkg galactosamine intraperitoneally. 
Cytosol was injected intraperitoneally 24 hr after the administration 
of galactosamine. The values for antipyrine in the cytosol treated-
rats and control rats were determined 48 and 72 hr after 
galactosamine injection. 
o: saline 
e : galactosamine 
o : galactosamine 
* : number of rats 
mean value + S.D. 
medium 
medium 
cytosol 
antipyrine (control rats) 
antipyrine (sham rats) 
antipyrine 
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7.3. Cpb:Wu rats treated with cytosol 
Cytosol was intraperitoneally injected 24 hr after injection of 
a sub-lethal dose (1000 mg/kg) of galactosamine. The same volume of 
medium alone was injected into rats as sham treatment 24 hr after 
galactosamine administration. The antipyrine elimination test was 
performed 48 and 72 hr after the injection of cytosol or injection of 
medium, i.e. , 72 and 96 hr after galactosamine. This time interval 
was chosen based on the course of antipyrine half-life values in the 
Cpb:Wu rat, as reported in Chapter 3. Only one test was done in each 
rat. The same test was perforrned in the control rats given saline 
instead of galactosamine. 
Figure 7. 3 shows the half-life values of antipyrine. In the sham 
rats given medium alone instead of cytosol the values decreased 
significantly (1.45 ..:!:. 0.2 to 6.18 + 1.8) 72 hr after galactosamine 
(p<O. 01) . The elimination rate of antypirine in rats given cytosol 
intraperitoneally 24 hr after galactosamine did not differ 
significantly from the values obtained in the sham rats. Three rats 
died before the antipyrine clearance test could be done. 
7.4. Conclusions 
The conclusions drawn in Chapter 6 hold equally for Lewis and 
Cpb:Wu strains. The results of the same treatment modalities applied 
to these rat strains did not reflect causal differences that could 
explain the negative results obtained in the WagjRij strain. In this 
model of acute hepatic failure, treatment with hepatocytes and 
hepatocyte fractions failed to stimulate the liver sufficiently for 
adequate recovery. 
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Fig. 7.3. 
Half-life values for serum antipyrine in Cpb:Wu rats treated with 
cytosol, after receiving 1000 mg/kg galactosamine intraperitoneally. 
Cytosol was injected 24 hr after the administration of galactosamine. 
The half-life values for antipyrine in the cytosol-treated rats and 
the control rats were detemined 48 and 72 hr after galactosamine 
injection. 
o: saline 
• : galactosamine 
o : galactosamine 
* : number of rats 
- · mean value + S.D. 
medium 
medium 
cytosol 
antipyrine (control rats) 
antipyrine (sham rats) 
antipyrine 
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CHAPI'ER 8 
Auxiliary partial liver transplantation 
======================================= 
All treatment modalities investigated in this study failed so 
far to increase the survival rate or to have a restorative effect on 
the deteriorated liver function. With respect to auxiliary partial 
liver transplantation (APLT) the question as to whether the liver 
cell damage is reversible, is of equal :importance. If the injury is 
irreversible and will terminate in necrosis, replacement of the liver 
function by transplantation of a donor liver is the only solution. If 
the damage is still reversible but not spontaneously, the hepatocytes 
of the donor liver can be expected to promote recove.r:y. A graft 
offers two main advantages. First, the hepatocytes will adapt and 
start to function normally much sooner than isolated hepatocytes 
would, and second, damage to the hepatocytes is more likely to be 
:imflicted by the isolation procedure than by the transplantation. 
Both of these factors should have a favorable influence on the 
process of regeneration. 
For the presented study we started by transplanting 30% of a 
normal donor liver into rats with a normal liver and following the 
graft for eight days . After that we transplanted 30% of a normal 
liver into rats given various doses of galactosamine. 
8.1. Transplantation of normal liver tissue into normal rats 
Twelve normal rats received a graft consisting of 30% of a 
normal liver. All of the animals survived the operation. Rats were 
killed 1, 2, 3, and 8 days after the transplantation. Autopsy showed 
no sign of pathology in the contents of the abdomen or the graft. 
Histological examination of liver biopts showed normal liver tissue 
up to three days after transplantation. From the third to the eighth 
day the graft decreased in size to 30% and became pale. 
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Histologically 1 an abundance of connective tissue was seen. 
Inunediately after circulation of the blood was restored 1 the 
graft became swollen. About ten minutes later1 the graft had adapted 
to the arterial pressure (27) through the portal vein and the 
swelling decreased 1 which persisted until the third day after the 
transplantation. The graft started to produce bile within 10 minutes 
after the commencement of blood flow. 
8. 2. Transplantation of nonnal liver tissue into rats 
treated with galactosamine 
The effect of transplantation of 30% of a normal liver on the 
survival rate after intraperitoneal administration of various doses 
of galactosamine was investigated. Table 8. 1 shows the survival rate 
of the rats given normal liver tissue. 
The group of rats which received 1000 mgjkg galactosamine 
developed the most severe clotting problems 1 and therefore the 
operation was technically the most difficult to perform in these 
animals. All of the grafted rats survived the operation. Those which 
received only galactosamine (controls) lived 5 hr longer than the 
rats given a graft (APLT). The sham-operation rats died 4 hr earlier 
than the APLT rats. Samples of liver from the control rats 1 the sham-
operation rats 1 and both the grafted and the recipient 1 s liver were 
studied. All samples showed diffusely distributed} severely necrotic 
liver tissue whose architecture had disappeared. 
The group of rats with 600 mgjkg galactosamine gave fewer 
surgical problems . The sham-operation rats died even earlier than the 
controls and the APLT rats 1 but significantly (p<O.OS) more control 
rats survived than sham or APLT rats. Histologically} the sham rats 
showed severely necrotic liver tissue. The liver samples of the APLT 
rats and the controls (all of which died) was also necrotic but the 
livers of the APLT rats showed less damage than those of the control 
rats. 
The rats of the groups which were given 1000 and 600 mg/kg 
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galactosamine and died after receiving a graft or sham operation 
showed the symptoms of acute hepatic coma. 
In the group given 300 mgjkg galactosamine, survival differed 
significantly (p<0.001) ,between the sham-operation and the grafted 
animals. The divergence was most striking in this group. Besides the 
significant difference in survival after transplantation, there were 
histological differences (Fig. 8. 2 - 8. 5) between the host liver and 
the graft. The samples of the host and graft liver tissue showed a 
normal architecture and normal healthy hepatocytes, whereas those of 
the rats which received a sham operation showed a severe loss of 
liver architecture and a diffusely necrotic parenchyme. 
The group given 150 mg/kg galactosamine showed histologically 
normal liver tissue with the same quality as that of the 
transplantated normal rats. 
Figure 8.1 shows a liver graft 48 hr after transplantation. The 
acceptor rat had received an injection of 300 mgjkg galactosamine 
20 hr before the transplantation. 
Figure 8.6 shows a section liver tissue from a normal healthy 
rat biopsied 24 hr after 70% hepatectomy. The striking difference 
here is that, unlike the liver tissue of all grafts, hosts, and sham-
operation rats, the remaining liver tissue of the partially 
hepatectomized rats showed a high frequency of mitotic figures. None 
of the sections of the liver tissue of rats treated with 
galactosamine showed signs of mitosis, regardless of the dosage. 
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Table 8ol. 
Survival rate of WagjRij rats given various doses of galactosamine 
before grafting of 30% of a nonnal rat liver (APLT) 0 
mg/kg A 8 c 
Galactosamine APLT Sham Controls 
1000 * 0/6 0/6 0/10 
600 0/6 c 0/6 c 7/10 
300 10/12 a,b 0/12 d 10/10 
150 5/5 5/5 10/10 
* = Number of survivors/TOtal number of rats 
A = Transplantation of 30% of a donor liver 24 hr after galactosamine 
injection 
B = Sham transplantation 24 hr after galactosamine injection 
C = Rats given only galactosamine 
a p < 00001 compared with sham-transplantation rats 
b nos 0 compared with control rats 
c p < 0 0 05 compared with control rats 
d p < 0 0 001 compared with control rats 
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Fig. 8.1. 
Liver graft 48 hr after transplantation into a rat given 300 rng/kg 
galactosamine. 
Fig. 8.2. 
Light-microscopical section of liver tissue of a host liver 48 hr 
after administration of 300 rng/kg galactosamine. HE. x 250. 
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Fig. 8.3. 
Light-microscopical section of liver tissue of a host liver given 300 
mg/kg galactosamine and 20 hr after sham operation. HE. x 250. 
Fig. 8. 4. 
Light-microscopical section of host liver tissue 48 hr after 
administration of 300 mg/kg galactosamine and 24 hr after 
transplantation of 30% of normal liver tissue. HE. x 250. 
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Fig. 8.5. 
Light-microscopical section of liver tissue from a graft transplanted 
24 hr after the donor had received of 300 mg/kg galactosamine. 
HE. X 600. 
Fig. 8.6. 
Light-microscopical section of normal liver tissue 24 hr after 70% 
hepatectomy. HE. x 250. 
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8. 3. Conclusions 
We were able to transplant 30% of a nonnal isogenic liver in 
rats which were in bad condition and had severe blood-clotting 
problems. All recipient rats survived the critical six hours after 
both the transplantation and the sham operation. Death was due to 
acute hepatic failure and not to effects of the operation. The 
finding that significantly more rats survived after receiving 
galactosamine only than after the sham operation (Table 8.1,d) 
indicates that the operation inflicted further damage on the livers 
already injured by galactosamine. This suggests that sub-lethal 
damage might be made lethal by the operation. 
Transplantation of 30% of a normal liver improved the survival 
rate significantly in rats which had received 300 mg/kg galactosamine 
as distinct from those given 300 mgjkg galactosamine and a sham 
operation (Table 8. 1, a). Furthermore, survival was significantly 
higher in rats given galactosamine alone instead of galactosamine and 
a sham operation (Table 8.1). 
Group C in Table 8.1 received only galactosamine. Comparison of 
this group with the groups of grafted (A) and sham-operation rats (B) 
shows that the best survival rate was achieved after administration 
of 300 and 600 mg/kg galactosamine and no further treatment. 
The effect of the donor liver seems to have been due to 
temporary detoxification rather than to stimulation of the host liver 
to regenerate. If we compare the histological findings in the graft 
and the host liver at the four galactosamine dosages it is evident 
that the cellular damage increased with increasing dose in both the 
graft and the host liver. The liver biopts of the sham-operation rats 
showed more damage at all four doses of galactosamine than the host 
livers and the grafts did. Histologically the same severe damage was 
seen in the biopts of livers of the sham-operated rats and the rats 
given 300 mg/kg galactosamine and a graft liver but which died (2/12) 
after the operation (Table 8.1). This suggests that the graft's 
capacity for detoxification was inadequate in the transplanted 
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animals . Histological examination also showed that there was a strong 
increase of synthesis by the hepatocytes of rats which had received 
300 mgjkg galactosamine and survived (10/12). This increased activity 
was accompanied by an enlargement of the nucleolus which also shifted 
to the center of the nucleus (13). These prominent nucleoli occured 
frequently in the section of l::oth the graft and the host liver, but 
were not seen in the rats which did not survive (Table 8. 1) . 
An elevated mitotic rate was observed in liver tissue of normal 
healthy rats biopsied 24 hr after 70% hepatectomy. None of the liver 
biopts of APLT rats showed mitotic figures in either the graft or the 
host liver. 
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CHAPTER 9 
GENERAL DISCUSSION 
The results of several investigations indicate that acute liver 
failure induced by a toxic substance responds to treatment with 
viable isolated hepatocytes ( 15,48-52,62,78,80 ,84, 90), a homogenate 
or cytosol (60,88) of normal or regenerating (20,63,64,88) liver 
tissue, and cell-free supernatant (2,65,66). The existence of a 
trophic factor that stimulates regeneration in the liver was 
postulated (10,37,38,61,81-83). Significantly more rats were expected 
to survive poisoning with a lethal dose of galactosamine after these 
forms of treatment. 
The discrepancy between the results reported in the literature 
and our observations concerning the effects of implantation of 
hepatocytes on the survival rate (Chapter 5) might be explained by 
the difference in the duration of the interval between the time of 
hepatocyte implantation and the death of the animals. In the design 
of this type of experiment two periods are of paramount importance. 
The first is the interval between the injection of galactosamine and 
the implantation of the hepatocytes, and the second is the interval 
between the implantation of the hepatocytes and death, taken as the 
mean survival time after galactosamine in the absence of treatment. 
Figure 9.1 includes the survival-time intervals reported by 
several investigators. A mean survival time of 96 hr without 
treatment was reported by Makowka (46,48-52), who concluded that 
transplantation of 40x106 liver cells into the abdomen could improve 
the survival rate in rats suffering from galactosamine-induced acute 
liver failure if the cells were transplantated 24 or 48 hr after 
galactosamine injection. However, transplantation of hepatocytes was 
ineffective if it occurred 60 hr or longer after galactosamine 
injection. 
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+ + 
Oh 24h 48h 60h 96h 
+ 
II 
Oh 48h 72h 
+ 
Ill 
Oh 20h 28h 50h 
IV 
Oh 6h 12h 24h 48h 
Fig. 9.1. 
Intervals between galactosamine poisoning, treatment with isolated 
liver cells, and maximum mortality, in the published studies and the 
present investigation. 
I. Makowka (52): Lewis rat; galactosamine 2600 mgjkg; hepatocytes 
implanted in the abdomen. 
II. Sommer et al.(80): Lewis rats; galactosamine 1100 mgjkg; 
hepatocytes implanted in the abdomen, spleen, and liver. 
III.Baumgartner et al. (2): Fisher rat; galactosamine 500 mgjkg; 
hepatocytes implanted in the spleen. 
IV. Present study: Wag/rij rat; galactosamine 1000 mgjkg; hepatocytes 
implanted in the abdomen. 
Numbers under the horizontal lines give the time (in hours) after 
administration of galactosamine at which the hepatocytes were 
injected in the different compartments. The last numbers on the right 
give the time of maximum mortality in the absence of treatment. 
Different groups of rats were used for each interval after 
galactosamine. 
+ treatment which improved the survival rate 
- = treatment which did not improve the survival rate 
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In the experiments done by Sommer et al. (80) the mean survival time 
was about 72 hr and transplantation of 20x106 liver cells into the 
liver or spleen 48 hr after the injection of galactosamine enhanced 
the survival rate of the rats. Baumgartner et al. (2) found a mean 
survival time of 50 hr for rats given galactosamine. Intrasplenic 
transplantation of 10-20x106 liver cells improved the survival if 
given 20-28 hr after galactosamine, whereas earlier or later 
implantation did not. The published data indicate that the interval 
between galactosamine injection and the transplantation of 
hepatocytes must be at least 20 hr. Hepatocytes implanted after a 
shorter interval can be damaged by the effects of galactosamine. 
According to these reported findings the interval between 
transplantation and the mean survival time should be at least 22 or 
36 hr, to give the implanted hepatocytes sufficient time to influence 
the process of liver cell necrosis induced by galactosamine. In the 
present study the maximum mortality occurred during the second night, 
about 48 hr after the a&ninistration of galactosamine. Comparison of 
the experimental schedule used in the present study with the 
protocols of the other three studies showed that for the rats given 
hepatocytes 6 or 12 hr after galactosamine injection, the interval 
between injection of the compound and transplantation of the cells 
was less than 20 hr. For the rats rats given the hepatocytes 24 hr 
after galactosamine injection, the interval between transplantation 
and the mean survival time was less than 22 hr. Thus, it seems 
possible that the implanted hepatocytes and hepatocyte fractions 
failed to improve the survival rate either because of the late 
effects of galactosamine or because the period in which they could 
contribute to the reversal of liver degeneration by stimulating 
regeneration was too short. 
One critical factor in the present animal model of acute liver 
failure is that although the death of the animals from acute liver 
failure must occur within a limited interval, they must survive long 
enough to allow time for treatment to take effect. As already 
mentioned, the interval between a&ninistration of a lethal dose of 
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galactosamine and the mean survival time in our study was rather 
short ( 48 hr), and the implanted hepatoytes might not have had 
sufficient time to influence the processes of degeneration and/or 
regeneration. To lengthen this interval we wanted to use uridine in a 
dose that would prevent cell death if given at the same time as 
galactosamine but not if given as late as 6 hr after galactosamine. 
This would also eliminate the possibly deleterious effect of uridine 
deficiency on the transplanted cells. According to Farber and 
co-workers (18), uridine prevents liver cell necrosis if given up to 
3 hr after galactosamine injection but has no effect if given as late 
as 6 hr after galactosamine injection. These authors described an 
irreversible lesion developing within 3 to 6 hr after galactosamine 
injection and ultimately resulting in the death of the animals. In a 
more recent paper Rasenack and co-workers reported that the 
time-dependent effect of uridine on galactosamine-pretreated isolated 
rat livers was exactly the same as that found in the liver of normal 
rats (68). Isolated rat livers were initially perfused for 3 hr with 
a medium containing galactosamine. The addition of uridine to the 
perfusion medium up to 3 hr after galactosamine prevented or reversed 
the galactosamine-induced damage. Uridine added to the perfusion 
medium as late as 6 hr after galactosamine was ineffective. In our 
study the longest interval between the administration of 
galactosamine and uridine, during which uridine significantly 
enhanced the survival rate of WagjRij rats, lay between 12 and 18 hr. 
This interval is much longer than those reported in the literature. 
On the basis of the survival rate, we were unable to find an 
appropriate dose of uridine meeting our conditions . 
The second critical factor with respect to this model is that 
the hepatic lesion must be potentially reversible. It is possible 
that under the conditions we applied for the survival experiments the 
affected liver cells passed "the point of no return". For that reason 
we induced a spontaneously reversible grade of hepatic injury to be 
certain that the lesion is potentially reversible. The fact that 
implantation of hepatocytes failed to enhance the recovexy of the 
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liver function indicates that the length of the interval and the 
irreversibility are not sufficient to explain the negative results in 
the survival experiments. The liver function tests were performed up 
to 48 hr after implantation of the hepatocytes, i.e., 72 hr after the 
injection of galactosamine, allowing enough time for the implanted 
hepatocytes to affect the regeneration process. 
In a view of the substantial inter-strain differences (3,7,24,25) 
in the reaction to galactosamine, it is conceivable that the choice 
of the animal strain used for such studies on regeneration is of 
paramount importance. We induced a spontaneously reversible degree of 
hepatic injury in several rat strains (Chapter 7), and the failure of 
implanted hepatocytes to improve the recovery of the liver function 
indicates that the strain variation did not explain the negative 
results. 
As discussed, rats within different groups showed substantial 
variation of the degree of deterioration of the liver function 
following galactosamine administration. Tabata reported (87) that the 
LDso of rats for galactosamine varied widely between different 
batches of male WU rats with negligible differences in age and 
weight, which were supplied weekly by the same breeder. In the kind 
of experiments we performed, the number of control and treated rats 
must of course always be in the same range. 
A parameter which is equivalent to the survival time is not yet 
available, because the process underlying the death of liver cells is 
still poorly understood. When all of the normal structures and 
functions of dying cells are disturbed, it is difficult or impossible 
to determine whether a change in a particular parameter has to do 
with cause, or effect, of the dying cell. 
Liver transplantation seems to be the only remaining form of 
treatment to be evaluated with respect to the feasibility of 
improvement of the survival rate. But in the present study 
transplantation of 30% of a normal liver did not reverse lethal liver 
damage. Only rats given a sub-lethal dose of galactosamine survived, 
those given a sham operation as well, did not. It seems unlikely that 
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this is to be ascribed to the fact that the graft was only 
arterialized (27,93) and was not provided with portal blood. 
Consensus has not been reached on the question as to whether 
portal blood is essential for regeneration in the transplant or the 
host's liver. Studies done by Rozga (69,70) showed that the presence 
of factors originating from the portal blood is mandatory for 
regeneration. However, the presence of these factors in the systemic 
circulation is sufficient to stimulate regeneration (69). For our 
liver transplantation model it may be assumed that the poor 
functioning of the host's liver guarantees the presence of adequate 
levels of the regenerative factors in the circulation to make 
regeneration possible. It is relevant that Holmin (27), Saric (71), 
and Castaing (12) reported that arterialization of the liver through 
the portal vein improves the clearance capacity and they found no 
ultrastructural lesions. 
An important histological criterion for regeneration is an 
increase in the rate of mitosis, which we assessed after a 70% 
hepatectomy in normal rats. The mitotic rate increased within 24 hr, 
and one mitosis was found per field of vision at a magnification of 
400x. Histological sections of tissue from recipients surviving after 
300 mg/kg galactosamine showed no mitotic figures in either the graft 
or the host liver. We performed the transplantation 20 hr after the 
administration of galactosamine, because we had found that after 18 
hr the liver injur:y caused by galactosamine could not be reversed by 
uridine and spontaneous reversal was not expected 18 hr or longer 
after injection of galactosamine (Chapter 5). The positive effect of 
transplantation of 30% of a normal liver seen after administration of 
300 mg/kg galactosamine might mean that the graft's liver had 
undergone less than the critical amount of damage by secondary 
metabolites and had more time to regenerate/recover spontaneously, 
although we found no histological signs of regeneration. It seems 
probable that when higher doses of galactosamine were used the 
detoxification capacity of the graft was not adequate. 
If we compare the three groups of rats - the group given a 
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graft, the group which undeJ:Went a sham operation, and the group 
given only galactosamine - it is evident that one must be certain 
that spontaneous recovery is impossible before one undertakes a liver 
transplantation intended to aim at stimulation of recovery of the 
sick liver. 
The findings made in the presented study suggest that one or 
more still unknown facto:r:;s inherent in the experimental models 
currently in use are of critical importance and that only a certain 
limited type of model of acute hepatic failure is suitable for the 
evaluation of the effectiveness of methods intended to promote 
regeneration of diseased livers. 
It does not seem unreasonable to conclude that 40 x 106 liver 
cells injected into the abdominal cavity or the spleen would not 
improve survival, since ca. 300xlo6 (representing 30% of a normal 
liver) did not do so. It is conceivable that in a given model the use 
of hepatocytes and/or hepatocyte fractions triggers a non-specific 
reaction leading to survival. It is then also conceivable that when 
the hepatocytes or hepatocyte fractions are injected, the ongoing 
damage caused by galactosamine is arrested before it becomes lethal. 
This means that in cases of real fulminant hepatic failure the only 
chance of survival lies in the ability of the graft either to induce 
regeneration in the diseased liver or to take over all of the 
functions of the damaged liver. Because of the excessive risk 
associated with waiting to see whether the organ will recover is too 
great, it is preferable to aim at a transplantation enabling the 
graft to take over functions of the host's liver completely. 
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SUMMARY 
The mortality rate of patients suffering from acute hepatic 
failure remains very high. The basic therapeutic clinical approach is 
intensive-care monitoring aimed at preventing accumulation of the 
liver damage, the prevention of complications due to liver failure, 
and attempts to give the sick liver enough time to regenerate. 
Investigations concerning regeneration factors pointed to the 
existence of a hepatotrophic factor that might stimulate regeneration 
in a damaged liver at the moment when most of the hepatocytes have 
reached the point of no return. This regenerative capacity of the 
liver could be triggered experimentally by transplantation of viable 
isolated hepatocytes, hepatocyte fractions of normal and regenerating 
donor liver tissue, and supernatant of liver-cell cultures. In the 
hands of some investigators, these forms of treatment led to 
improvement of the survival rate of rats suffering from acute hepatic 
failure. This reduction of the mortality rate associated with acute 
hepatic failure led to the present investigations on the effect of 
the transplantation of viable isolated hepatocytes and hepatocyte 
fractions on the survival of rats suffering from acute liver failure 
induced by a toxic agent, in particular as a step toward evaluation 
of the method for clinical use in patients with acute hepatic 
failure. 
Chapter 2 deals with the materials and methods used in this 
research. For the evaluation of the therapeutic effect a model was 
needed, as discussed in Chapter 3 dealing with the dose-response 
relation of galactosamine, a substance which induces a liver damage 
in normal rats. The survival rate in two rat strains, BN and WagjRij, 
after injection of galactosamine was determined and the LDgo was 
estimated. The sensitivity of the Lewis, WagjCpb, and Cpb:Wu strains 
to galactosamine was also assessed. 
The effects of transplantation of viable hepatocytes and 
hepatocyte fractions on the survival rate of rats suffering from 
acute hepatic failure are described in Chapter 4. The WagjRij rats 
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were injected with a lethal dose of galactosamine, and the different 
treabnent modalities were administered 24 hr later. An improvement of 
the survival rate was not established for any of the forms of 
treabnent. A possible cause of this failure might be that the period, 
the interval between administration of the different treatment 
modalities and the mean survival time, in which the process of liver 
degeneration would be influenced was too short. We attempted to find 
a way to lenghten this interval by giving the treabnent sooner after 
galactosamine. 
Uridine is a substance which can prevent or reverse liver 
damage, depending on the dose and time of injection after 
administration of galactosamine. Chapter 5 describes the studies 
performed to determine the uridine dosage and schedule of 
administration such that the galactosamine-induced liver damage would 
not be reversed but the transplanted hepatocytes would be 
sufficiently protected against the effects of galactosamine. 
The negative results concerning improvement of the survival rate 
of rats suffering from acute hepatic failure might be explained by 
irreversibility of the induced liver damage. In Chapter 6 the 
induction of sub-lethal liver damage is described. We used specific 
liver function tests to determine whether any of the treatment 
modalities were able to stimulate recovery of a deteriorating liver 
function. These tests gave the same results as were obtained for 
improvement of the survival rate. We then induced sub-lethal liver 
damage in rats of two strains, Lewis and Cpb:Wu, as discussed in 
Chapter 7. These two strains were used to assess the effect of the 
treabnent modalities on deteriorating liver function in relation to 
differences in sensitivity to galactosamine. None of the forms of 
treabnent improved either the survival rate or the deteriorating 
liver function after a lethal or sub-lethal dose of galactosamine, 
respectively. 
Since the liver has been reported to possess a hepatotrophic 
factor, we transplanted 30% of a normal liver into rats given 
galactosamine in various dosages, as described in Chapter 8. Only 
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transplantation of 30% of a nonnal liver after given a sub-lethal 
dose of galactosamine gave improvement -of the survival rate compared 
with the sham-operated rats. Rats given the same dosage galactosamine 
alone survived spontaneously. 
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SAMENVA'ITING 
============ 
Het sterftepercentage van patienten lijdend aan een acuut 
leverfalen is erg hoog. De basale klinische benadering is momenteel 
intensive-care begeleiding, gericht op het voorkomen van een toe-
nemende leverschade, het voorkomen van complicaties ten gevolge van 
het leverfalen en pogingen om de zieke lever voldoende tijd te geven 
te regenereren. Onderzoekingen betreffende regeneratieve factoren 
wijzen op het bestaan van een hepatotrofe factor. Deze factor zou de 
leverregeneratie kunnen stimuleren op een moment dat de meeste 
hepatocyten zodanig beschadigd zijn, dat spontaan herstel niet meer 
mogelijk is. Het regeneratievermogen van de lever kan experimenteel 
in werking gezet worden door transplantatie van levensvatbare 
geisoleerde hepatocyten, of hepatocytenfracties van normaal en 
regenererend donor leveiWeefsel of supernatant van levercelkweken. 
Enkele onderzoekers konden een verbetering van het overlevings-
percentage van ratten, lijdend aan een acuut hepatisch falen, 
bewerkstelligen door toediening van deze geisoleerde hepatocyten en 
hepatocyten fracties·. De uitkomsten van die onderzoekingen dienden 
als basis voor dit onderzoek. Zowel het effect van transplantatie van 
geisoleerde hepatocyten, hepatocyten fracties, cytosol en supernatant 
op de overleving van ratten lijdend aan een acuut lever falen is 
onderzocht en beschreven en de eventuele klinische toepassing daarvan 
bekeken. 
Hoofdstuk 2 behandelt de materialen en methoden gebruikt in dit 
onderzoek. Om een therapeutis ch effect te kunnen evalueren is een 
model nodig. In hoofdstuk 3 wordt de dosis-effect relatie van 
galactosamine beschreven, een stof welke een leverschade induceert in 
gewone ratten. Het overlevings percentage van twee ratten stammen, de 
BN en de Wag/Rij, na het injecteren van galactosamine is bepaald en 
de LDgo is geschat. Tevens is de gevoeligheid voor galactosamine van 
de Lewis, WagjCpb en Cpb:Wu stammen beoordeeld. De effecten van 
transplantatie van vitale geisoleerde hepatocyten, hepatocyten-
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fracties, cytosol en supernatant op het overlevingspercentage van 
ratten, lijdend aan een acuut leverfalen, zijn beschreven in 
hoofdstuk. 4. De WagjRij ratten zijn geinjecteerd met een lethale 
dosis galactosamine, en de verschillende behandelingsvo.nnen zijn 24 
uur later toegediend. Een verbetering van het overlevingspercentage 
voor alle vo.nnen van behandeling werd niet verkregen. Een mogelijke 
oorzaak van dit falen kan zijn dat de gemiddelde overlevingstijd na 
de toediening van de behandeling te kort is om het proces van 
leverdegeneratie te beinvloeden. Een manier om dit interval te 
verlengen is door de behandeling sneller toe te dienen na de injectie 
met galactosamine. 
Uridine is een stof die de aan te brengen leverschade kan 
voorkomen of doen herstellen, afhankelijk van hoeveelheid en moment 
van injectie na toediening van galactosamine. Hoofdstuk. 5 beschrijft 
de onderzoekingen welke zijn verricht om een dosering uridine te 
bepalen en het t ij ds chema van toediening, zodanig dat de 
galactosamine-geinduceerde leverschade niet hersteld wordt maar de 
getransplanteerde hepatocyten voldoende besche.nnd worden tegen de 
effecten van galactosamine. 
De negatieve resultaten met betrekking tot de verbetering van het 
overlevingspercentage van ratten lijdend aan een acuut leverfalen zou 
verklaard kunnen worden door de irreversibiliteit van de geinduceerde 
leverschade. In hoofdstuk 6 is het toebrengen van een sublethale 
leverschade beschreven. Specifieke leverfunctietesten zijn gebruikt 
om te bepalen of een van de behandelingsvo.nnen in staat zou zijn het 
herstel van een verslechterende leverfunctie te stimuleren. Deze 
testen tonen dezelfde resultaten als welke zijn verkregen bij de 
onderzoekingen naar de verbetering van het overlevingspercentage. 
Vervolgens is een sublethale leverschade in 2 rattenstammen, te weten 
de Lewis en de Cpb:Wu, geinduceerd hetgeen is besproken in 
hoofdstuk 7. Deze twee rattenstammen zijn gebruikt om het effect van 
de behandelingsvo.nnen te toetsen bij een afnemende leverfunctie in 
relatie met een verschil in gevoeligheid voor galactosamine. Geen van 
de vo.nnen van behandeling verbeterden het overlevingspercentage of de 
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afnemende leverfunctie na een lethale resp. sublethale dos is 
galactosamine. 
Aangezien wordt aangenomen dat de lever na parti~le hepatectomie 
een hepatocyt-prolifererende factor uitscheidt, transplanteerden wij 
30% van een normale lever in ratten behandeld met verschillende doses 
galactosamine, zoals beschreven in hoofdstuk 8. Alleen bij de groep 
ratten die een sublethale dosis galactosamine en 30% normaal donor-
leverweefsel kregen is een verbetering van het overlevingspercentage 
geconstateerd in vergelijking met de "sham" geopereerde ratten. 
Ratten die alleen de sublethale dosering galactosamine kregen, 
overleefden spontaan. 
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APLT 
ATP 
CTP 
c:v 
d-Gl 
GTP 
PVG 
RIA 
RK/LK 
sc 
SCVG 
UDP 
UDP-galactose 
UDP-GalN 
UDP-GalNac 
UDP-GlcN 
UDP-GlcNac 
UDP-glucose 
UDP-glucuronate 
UMP 
UTP 
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List of abbreviations 
===================== 
Auxiliary partial liver transplantation 
Adenosine 5 1 -triphosphate 
Cytidine 5'-triphosphate 
Caval vein 
Galactosamine 
Guanine 5 1 -triphosphate 
Portal vein graft 
Right iliac artery 
Right kidney/Left kidney 
Silastic cannula 
Superior caval vein graft 
Uridine 5 1 -diphosphate 
Uridine diphosphate galactose 
Uridine-galactosamine 
Uridine diphosphate N-acetyl-galactosamine 
Uridine-glucosamine 
Uridine diphosphate N-acetyl-glucosamine 
Uridine diphosphate glucose 
Uridine diphosphate glucuronate 
Uridine 5 1 -rnonophosphate 
Uridine 51 -triphosphate 
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